[[ဝှာင်:Covid19 vaccine biontech pfizer 2.jpg|thumb|ဗီုရုပ်ဝက်သိန် ကဝ်ဝိဒ်-၁၉ နူကဵု ဖရိဇြာ]]

{{short description|Potential vaccine or vaccines against COVID-19}}
[[File:COVID-19 vaccine map.svg|thumb|right|400px|
ဗီုတိ မထ္ၜး ဍုင်မပဒတန် ဝက်သိန်ဂမၠိုင်
{{legend|Green|Approved for general use, mass vaccination underway}}
{{legend|SpringGreen|[[:w:Emergency Use Authorization|{{abbr|EUA|emergency use authorization}}]] granted, mass vaccination underway}}
{{legend|DarkOrange|{{abbr|EUA|emergency use authorization}} granted, limited vaccination}}
{{legend|Blue|Approved for general use, mass vaccination planned}}
{{legend|DodgerBlue|{{abbr|EUA|emergency use authorization}} granted, mass vaccination planned}}
{{legend|Gold|{{abbr|EUA|emergency use authorization}} pending}}]]

'''ဝက်သိန် ကဝ်ဝိဒ်-၁၉'''  ({{Lang-en| '''COVID‑19 vaccine'''}}) ဂှ် ဒှ် ဝက်သိန် မပကဵု ညံင်[[ဒြဟတ်အိမ်မုန်]]မသ္ဂောအ်တီ သွက်ဂွံဒစဵုဒစး ယဲကဝ်ဝိဒ်-၁၉။ ကိုပ်ကၠာ ကပ်ယဲကဝ်ဝိဒ်-၁၉ ဟွံကတဵုဒှ်ဏီဂှ်ရ၊ တၠပညာတအ် ကၠောန်ပ္တိတ်လဝ် ဝက်သေန် သွက်ဂွံဗတိုက် ကဝ်ရဝ်နာဝဳရုသ် မပကဵု ညံင်ဂွံဒှ်ယဲသာ (SARS) ကေုာံ ယဲမာ (MERS)တုဲ တၠပညာတအ် တီကၠိုဟ်လဝ် ပရူလဒက်ပ္တန် ကေုာံ တၠုင်လအာ ကဝ်ရဝ်နာဝဳရုသ်ရ။ ကာလ ကဝ်ရဝ်နာဝဳရုသ်ဂကူတၞဟ် မပကဵု ညံင်ဂွံဒှ် ယဲကဝ်ဝိဒ်-၁၉ မကတဵုဒှ် ပ္ဍဲတမ်သၞာံ ၂၀၂၀ ဂှ် ညးတအ် စဂစာန်ကၠောန် ဝက်သိန်-ကဝ်ဝိဒ်-၁၉။ 

စိုပ်ၜိုတ် လဒေါဝ်ဒဳဇြေမ်ဗါ ၂၀၂၀ ဂှ် လၟောဝ်ဝက်သိန် ၅၇ ဂှ် ဂစာန်ကၠောန် ပဒၟံင်သုတေသနဂဥုဲတုဲ ပၞောဝ်တအ်ဂှ် ၄၀ ဂှ် နွံဒၟံင် ကဆံင်ကာလစွမ် ပထမ - ဒုတိယတုဲ ၁၇ ဂှ် နွံဒၟံင် ကဆံင်ကာလစွမ် ဒုတိယ - တတိယ။ ပ္ဍဲကဆံင်ကာလစွမ်တတိယဂှ် ဝက်သိန် ကဝ်ဝိဒ်-၁၉ ဗွဲမဂၠိုင် ကၠောန်ကမၠောန် ၜိုတ် ၉၅% သွက်ဂွံစဵုဒၞာ ယဲကဝ်ဝိဒ်-၁၉။<ref>{{Cite web|last=Santiago|first=Jahleah|date=2020-12-19|title=A side-by-side comparison of the Pfizer/BioNTech and Moderna vaccines|url=https://www.statnews.com/2020/12/19/a-side-by-side-comparison-of-the-pfizer-biontech-and-moderna-vaccines/|url-status=live|archive-url=|archive-date=|access-date=2020-12-24|website=STAT|language=en-US}}</ref> ဝက်သိန်လ္ၚဵုတအ်ဂှ် ဍုင်လ္ၚဵု ပဒတန်တုဲ ဝက်သိန်လ္ၚဵုတအ်ဂှ် ဍုင်လ္ၚဵု ဟွံပဒတန်ရ။ သီုဖအိုတ် မဂွံဒုင်ပဒတန် နကဵု အေဂျေန်သဳ ထတ်ယုက်ဍုင်တအ်ဂှ် နွံ မသုန် မပ္တံကဵု တဝ်ဇြဳနာမေရန် (Tozinameran) မကၠောန်ပ္တိတ် နူကဵု ဖြိဇြေရ်-ဗဳသြတေက် (Pfizer–BioNTech)၊ ဗဳဗဳဗ်-ကောဝ် (BBIBP-CorV) မကၠောန်ပ္တိတ် နူကဵု သဳနဝ်ဖာမ် (Sinopharm)၊ ကဝ်ရဝ်နာဝက် (CoronaVac) မကၠောန်ပ္တိတ် နူကဵု သဳနဝ်ဝက် (Sinovac)၊ အာမ်အာနာ-၁၂၇၃ (mRNA-1273) မကၠောန်ပ္တိတ် နူကဵု မဝ်ဒေရ်နာ (Moderna) ကေုာံ ဂမ်-ကဝ်ဝိဒ်-ဝက် (Gam-COVID-Vac) မကၠောန်ပ္တိတ် နူကဵု  အေန်သတဳကျုတ်သုတေသနဂမလေယာ (Gamaleya Research Institute)။ 

ဖြိဇြေရ်၊ မဝ်ဒေရ်နာ ကေုာံ သြသတြဇြေနေက (AstraZeneca) တအ် ဟီုလဝ် ပ္ဍဲသၞာံ ၂၀၂၁ မ္ဂး ညးတအ် ကၠောန်ပ္တိတ် လၟိဟ် ၅.၃&nbsp;ဗဳလဳယာန် သွုင် မာန်တုဲ ကလိဂွံ မၞိဟ်ၜိုတ် ၃ ဗဳလဳယာန်မာန် (မၞိဟ်မွဲမ္ဂး ဒးထ္ပက် ၂ သွုင်/တၞိင် သွက်ဂွံစဵုဒၞာ ကဝ်ဝိဒ်-၁၉)၊ ပ္ဍဲဂိတုဒဳဇြေမ်ဗါဂှ် နူကဵု ဍုင်နာနာတအ် ဗကန်လဝ် နူကဵုဌာနပ္တိတ်ဝက်သိန်တအ် လၟိဟ် ၁၀ ဗဳလဳယာန်ပြင်င်<ref name="mullard">{{cite journal|first1=Asher | last1=Mullard |date=30 November 2020|title=How COVID vaccines are being divvied up around the world Canada leads the pack in terms of doses secured per capita|url=https://www.nature.com/articles/d41586-020-03370-6|journal=Nature|doi=10.1038/d41586-020-03370-6|pmid=33257891|access-date=11 December 2020|s2cid=227246811}}</ref> ကဝက်ပြင်င်ဂှ် ဍုင်ပိုန်ဒြပ်ဇၞော်မောဝ်တအ် ဗကန်လဝ်တုဲ ဟီုကဵုလၟိဟ်မၞိဟ်ဂၠးကဝ်မ္ဂး ဍုင်သေဋ္ဌဳတအ်ဂှ် လၟိဟ်မၞိဟ် နွံ ၁၄% ဓဝ်ရ။<ref name="So">{{cite journal|last=So|first=Anthony D|last2=Woo|first2=Joshua|date=December 2020|title=Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis|journal=BMJ|page=m4750|doi=10.1136/bmj.m4750|issn=1756-1833|name-list-style=vanc|doi-access=free}}</ref> ဍုင်ဗွဲမဂၠိုင်တအ်ဂှ် ဖျေဟ်လၟေင်ကမၠောန် ထပက်ဝက်သိန် နကဵု မၞိဟ်ဗယု၊ ယဲဇမၠိင် မဒှ်မၞိဟ်အန္တရာယ်ဇၞော် ကုယဲကဝ်ဝိဒ်-၁၉ ကေုာံ အစာဂဥုဲ အစာသဝ်ဂှ် ကဵုထ္ပက်ကၠာရ။<ref>{{Cite news|last=Beaumont|first=Peter|date=2020-11-18|title=Covid-19 vaccine: who are countries prioritising for first doses?|language=en-GB|work=The Guardian|url=https://www.theguardian.com/world/2020/nov/18/covid-19-vaccine-who-are-countries-prioritising-for-first-doses|access-date=2020-12-26|issn=0261-3077}}</ref>

==လၟေင်ကမၠောန် ကေုာံ ဓလိုက်တမ်ရိုဟ်==
ပ္ဍဲမွဲဒမြိပ်သၞာံ ၂၀၂၀ နူစ သၞာံမံက်၊ ယဲကပ်စကတဵုဒှ်ဂှ် ဌာနမကၠောန်ပ္တိတ်ဂဥုဲဂမၠိုင်၊ အလဵုအသဳဍုင် ကေုာံ ကမ္မဏဳမဆေင်ကဵုဇဳဝဗေဒ နူကဵု ရးနိဂီုနာနာ ပ္တိတ်အာရီု ဂစာန်ကၠောန်ကၠုင် သွက်ကလိဂွံ ဝက်သိန်ကဝ်ဝိဒ်-၁၉ အိုတ်ရ။<ref name="thanh2">{{cite journal|last1=Le|first1=Tung Thanh|last2=Cramer|first2=Jakob P.|last3=Chen|first3=Robert|last4=Mayhew|first4=Stephen|date=4 September 2020|title=Evolution of the COVID-19 vaccine development landscape|journal=Nature Reviews Drug Discovery|volume=19|issue=10|pages=667–68|doi=10.1038/d41573-020-00151-8|issn=1474-1776|pmid=32887942|doi-access=free|s2cid=221503034|name-list-style=vanc}}</ref> အတိုင် ဂကောံပံင်ကောံမခၞံဗဒှ်သွက်စဵုဒၞာကပ်ယဲ (Coalition for Epidemic Preparedness Innovations -CEPI) မဗမံက်ထ္ၜးလဝ်မ္ဂး ဂကောံမပါလုပ် ပ္ဍဲအရာမကၠောန်ပ္တိတ် ဝက်သိန်ဏအ်ဂှ် နူကဵု အမေရိသၟဝ်ကျာဂှ် ၜိုတ် ၄၀%၊ အာရှ ကဵု အဝ်သတြေလျာ ၃၀%၊ ဥရောပ ၂၆% တုဲ ပ္ဍဲအမေရိသၠုင်ကျာ ကဵု အာဖရိကဂှ် ပါလုပ်ညိညကီုရ။<ref name="thanh2" /><ref name="thanh" />

လၟောဝ်ဝက်သိန်မွဲမွဲ ဂွံကလိဂွံဇမၞးမာန်ဂှ် ဒးအိုတ်သြန် ဗွဲမဂၠိုင်ဂၠေင်ရ။ ဥပမာ ခရိတ်င္ၚုဟ်အိုတ် ပ္ဍဲ ကာလစွမ်မၞိဟ်အလန်ပထမဂှ်သၟးဂှ် ဒးအိုတ် သြန်ဒဝ်လာအမေရိကာန် အကြာ ၁၄ မဳလဳယာန်ကဵု  ၂၅ မဳလဳယာန်။<ref name="gouglas">{{cite journal|vauthors=Gouglas D, Thanh Le T, Henderson K, Kaloudis A, Danielsen T, Hammersland NC, Robinson JM, Heaton PM, Røttingen JA|date=December 2018|title=Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study|journal=Lancet Global Health|volume=6|issue=12|pages=e1386–96|doi=10.1016/S2214-109X(18)30346-2|pmc=7164811|pmid=30342925}}</ref><ref name="dimasi">{{cite journal|vauthors=DiMasi JA, Grabowski HG, Hansen RW|date=May 2016|title=Innovation in the pharmaceutical industry: New estimates of R&D costs|journal=Journal of Health Economics|volume=47|pages=20–33|doi=10.1016/j.jhealeco.2016.01.012|pmid=26928437|doi-access=free|hdl-access=free|hdl=10161/12742}}</ref> ယဝ်ဒးပတုပ် နကဵုဥပမာမ္ဂး အခိင်ကာလ ကပ်ယဲအဳဗဝ်လာဝဳရုသ် (Ebola virus) မကတဵုဒှ် အကြာ ၂၀၁၃-၁၆ ဂှ် လၟောဝ်ဝက်သိန် သီုဖအိုတ် ဂစာန်ကၠောန် ၃၇ ဂှ် ဆဝက်သိန်မွဲဟေင် ကလိဂွံအခေါင်လာင်ဇြေန် သွက်ဂွံစကာ နဒဒှ် ဝက်သိန်၊ ညးမပ္တိတ်ဂှ် ခရိတ်စမ် ကာလစွမ်ဒုတိယ-တတိယဂှ် ဒးစကာသြန် ဒဝ်လာအမေရိကာန် ၜိုတ် ၁ ဗဳလဳယာန်။<ref name="gouglas"/>

=== ဂကောံ ရးနိဂီုနာနာ ===

====Access to COVID-19 Tools (ACT) Accelerator ကေုာံ COVAX====

ပရေင်ပံင်ကောံ ဂကောံဂၠးကဝ်နာနာ မပ္တံကဵု ဂကောံထတ်ယုက်ဂၠးကဝ် (WHO)၊ ဂကောံပံင်ကောံ သွက်ဂၠိုက်ဂၠာဲ အရာမဒစဵုဒစး ကပ်ယဲ(CEPI)၊ GAVI၊ Gates Foundation ကေုာံ သၟိင်ဍုင်ဂမၠိုင် ပံင်ကောံတုဲ ဒက်ပ္တန်လဝ် အေသဳတဳ (ACT) မဂွံအဓိပ္ပါယ် ကလိဂွံ ကပေါတ်သွက်ယဲကဝ်ဝိဒ်-၁၉ တအ် ပံင်ကောံတုဲ ဂၠာဲသြန်ဗွဝ် သွက်ဂွံထံက်ပင် ကမၠောန်လ္ၚတ်သုတေသန၊ ပ္တိတ်ကပေါတ်စွမ်ယဲ၊ ဂဥုဲလွဳ ကေုာံ ကဵုလာင်ဇြေန်ဝက်သိန် မဒှ်ပရေင်ကမၠောန် နကဵုက္ဍိုပ်လိက် "ကဝ်ဝဇ် ပိလ္လာရ် (COVAX Pillar)"။<ref name="who-covax">{{Cite web|date=2020|title=What is the ACT Accelerator?|url=https://www.who.int/initiatives/act-accelerator/about|url-status=live|archive-url=https://web.archive.org/web/20200925122714/https://www.who.int/initiatives/act-accelerator/|archive-date=25 September 2020|access-date=2020-08-29|publisher=World Health Organization}}</ref><ref name="covax-gavi-09">{{cite web|date=2020-09-01|title=What is COVAX?|url=https://www.gavi.org/vaccineswork/covax-explained|access-date=11 December 2020|publisher=GAVI}}</ref> နကဵု ကဝ်ဝက်ပိလ္လာရ်ဂှ် စွံလဝ် တင်ရန်တၟအ် ညံင်ဂွံကၠောန်ပ္တိတ် ဝက်သိန်ကဝ်ဝိဒ်-၁၉ ဗွဲမဂၠိုင်တုဲ လအိတ်သၞာံ ၂၀၂၁ မ္ဂး ညံင်ဂွံပ္တိတ် စဵုကဵု ၂ ဗဳလဳယာန်သွုင် သွက်ဂွံစဵုဒၞာ သၟာကမၠောန်ထတ်ယုက် ပ္ဍဲကိုပ်စၞေဟ် (frontline healthcare workers) ကေုာံ မၞိဟ်အန္တရာယ်ဇၞော် ကုကဝ်ဝိဒ်-၁၉ ပ္ဍဲဍုင်ဒိုက်ဂတ်တအ်ရ။<ref name="cepi-covax">{{cite web |title=COVAX: CEPI's response to COVID-19|url=https://cepi.net/COVAX/ |publisher=Coalition for Epidemic Preparedness Innovations (CEPI) |access-date=15 December 2020 |date=2020}}</ref><ref name="cepi-safer">{{cite web |title=New vaccines for a safer world |url=https://cepi.net/ |publisher=CEPI |access-date=15 December 2020 |date=2020}}</ref>

ဂိတုဒဳဇြေမ်ဗါ ၂၀၂၀ ဂှ် နကဵုအေသဳတဳ ပ္ကောံဂွံသြန်ဒဝ်လာအမေရိကာန် ၂.၄ ဗဳလဳယာန်တုဲ နကဵု ကဝ်ဝက် ကေုာံ CEPI ဂွံဆဵုကေတ် လၟောဝ်ဝက်သိန် ဒစိတ် ရ။ ဂကောံဏအ်ဂှ် ဒှ်ဂကောံဇၞော်အိုတ် မဆေင်ကဵု ပ္ဍဲအရာမပ္တိတ် ဝက်သိန် ကဝ်ဝိဒ်-၁၉တုဲ ပါလုပ်လဝ် သီုဖအိုတ် ဍုင် ၁၈၉ ရးနိဂီု။<ref name="cepi-portfolio">{{cite web |title=Our portfolio: partnerships to develop vaccines against COVID-19 |url=https://cepi.net/research_dev/our-portfolio/ |publisher=CEPI |access-date=15 December 2020 |date=2020}}</ref><ref name="who189">{{cite web|date=4 December 2020|title=Global equitable access to COVID-19 vaccines estimated to generate economic benefits of at least US$ 153 billion in 2020–21, and US$ 466 billion by 2025, in 10 major economies, according to new report by the Eurasia Group|url=https://www.who.int/news/item/03-12-2020-global-access-to-covid-19-vaccines-estimated-to-generate-economic-benefits-of-at-least-153-billion-in-2020-21|access-date=11 December 2020|publisher=World Health Organization}}</ref> သၞာံ ၂၀၂၀ လပါ်စဂှ် နကဵု ဂကောံထတ်ယုက်ဂၠးကဝ် ကလိဂွံ သြန်ထံက်ပင် နူကဵု ပန်စှ်ောဍုင် သြန်ဒဝ်လာအမေရိကာန် ၈ ဗဳလဳယာန် သွက်ဂွံကၠောန်ပ္တိတ် ဝက်သိန်ရ။<ref name="waked">{{Cite web|last=Wake|first=Damon|date=2020-05-04|title=EU spearheads $8 billion virus fundraiser|url=https://finance.yahoo.com/news/eu-hosts-virus-telethon-seeking-first-7-5-003500556.html|url-status=live|archive-url=https://web.archive.org/web/20200629033556/https://finance.yahoo.com/news/eu-hosts-virus-telethon-seeking-first-7-5-003500556.html|archive-date=29 June 2020|access-date=2020-05-04|publisher=Yahoo Finance|name-list-style=vanc}}</ref>

ဂိတုဂျူလာင်ဂှ် ဂကောံထတ်ယုက်ဂၠးကဝ် လလောင်တြး ဍုင် ၁၆၅ ဍုင် မပစၞးကု ကောန်မၞိဟ်ဂၠးတိ ၆၀% တုပ်စိုတ် အစဳအဇန်ကဝ်ဝက်တုဲ ကဵုလဝ် ဂတိပါင် တုပ်လဝ်စိုတ် ကၞောတ်သၞာံ ၂၀၂၁ မ္ဂး ကောန်ဍုင်ညးတအ် ၂၀% ဂှ် သ္ကလိဂွံ ဝက်သိန်ရောင်။<ref name="covax">{{cite press release |title=More than 150 countries engaged in COVID-19 vaccine global access facility |url=https://www.who.int/news-room/detail/15-07-2020-more-than-150-countries-engaged-in-covid-19-vaccine-global-access-facility |publisher=World Health Organization |access-date=25 July 2020 |date=15 July 2020 |quote=COVAX is the only truly global solution to the COVID-19 pandemic. For the vast majority of countries, whether they can afford to pay for their own doses or require assistance, it means receiving a guaranteed share of doses and avoiding being pushed to the back of the queue, as we saw during the H1N1 pandemic a decade ago. Even for those countries that are able to secure their own agreements with vaccine manufacturers, this mechanism represents, through its world-leading portfolio of vaccine candidates, a means of reducing the risks associated with individual candidates failing to show efficacy or gain licensure. |archive-date=15 July 2020 |archive-url=https://web.archive.org/web/20200715152301/https://www.who.int/news-room/detail/15-07-2020-more-than-150-countries-engaged-in-covid-19-vaccine-global-access-facility |url-status=live }}</ref>

ဂကောံပံင်ကောံဂၠးကဝ် သွက်စဵုဒၞာယဲကမၠောအ် (The Global Research Collaboration for Infectious Disease Preparedness - GLoPID-R) ဂှ် ပံင်တောဲကၠောန် ကုဂကောံထတ်ယုက်ဂၠးကဝ် ကေုာံ ရးနိဂီုဂမၠိုင် သွက်ဂွံကၠောန်ပ္တိတ် ဝက်သိန် ကဝ်ဝိဒ်-၁၉။<ref>{{Cite web |title=GloPID: Novel coronavirus COVID-19 |url=https://www.glopid-r.org/our-work/novel-coronavirus-covid-19 |website=glopid-r.org |access-date=2020-05-02 |archive-url=https://web.archive.org/web/20200502035337/https://www.glopid-r.org/our-work/novel-coronavirus-covid-19/ |archive-date=2 May 2020 |url-status=live | quote =GloPID-R Members and other major players involved in infectious disease outbreaks worldwide reacted rapidly to this emerging epidemic, working closely with the WHO to identify the specific funding research priorities needed to tackle the disease. }}</ref><ref name=can-research/>တုဲပၠန် International Severe Acute Respiratory ကေုာံ Emerging Infection Consortium တအ်ဂှ် ဒှ်ဂကောံလ္ၚတ်မကဵုပရိုင်တင်ဂၞင် ပညာ ပ္ဍဲအရာမပသုတေသန ကဝ်ဝိဒ်-၁၉ ကေုာံ ကဵုပညာကုညးဍုင်ကွာန်တအ် သီုကဵု ပ္ဍဲအရာမပရးဝက်သိန်တအ်ရ။<ref name="isaric">{{Cite web|title=ISARIC: COVID-19 clinical research resources|url=https://isaric.tghn.org/covid-19-clinical-research-resources/|date=2020-04-27|publisher=ISARIC|access-date=2020-05-02|archive-url=https://web.archive.org/web/20200330135638/https://isaric.tghn.org/covid-19-clinical-research-resources/|archive-date=30 March 2020|url-status=live}}</ref>

ပ္ဍဲ ၄ ဂျောန်ဂှ် ပူဂိုလ် ကေုာံ သၟိင်ဍုင်ဂမၠိုင် ကၠောန်ဗဒှ် ကောံဓရီုသကိုပ်သက သုမ္မိတ် (summit) ပ္ဍဲဍုင်လာန်ဒါန်၊ ယူကေ၊ ဂှ် မၞိဟ်နူ ၅၂ ဍုင် တိုန်စိုပ်၊ သကိုပ်သကဍုင် ၃၅ ဍုင်၊ နူကဵု ဂျဳ၇ တအ်ကီု သီုကဵု ဂျဳ၂၀ဂှ် ကလိဂွံ သြန်ဗွဝ် ၈ ဗဳလဳယာန် သွက်ဂွံထံက်ပင် မဟာမိတ်ဂၠးကဝ် သွက်ဝက်သိန် ကေုာံ အိမ်မုန် (Global Alliance for Vaccines and Immunisation - GAVI) သွက်ဂွံကၠောန်ပ္တိတ် ဝက်သိန် ကဝ်ဝိဒ်-၁၉တုဲ ကဵုဂဥုဲဝက်သိန် ကုကောန်ၚာ် ၃၀၀ ဗဳလဳယာန် မနွံပ္ဍဲဍုင်ဒိုက်ဂတ်တအ် ပ္ဍဲအကြာသၞာံ ၂၀၁၅ ရ။<ref name="gavi-summit">{{Cite web|title=Global Vaccine Summit 2020: World leaders make historic commitments to provide equal access to vaccines for all|url=https://www.gavi.org/news/media-room/world-leaders-make-historic-commitments-provide-equal-access-vaccines-all|access-date=2020-06-04|publisher=Global Alliance for Vaccines and Immunisation|date=2020-06-04|archive-url=https://web.archive.org/web/20200606161748/https://www.gavi.org/news/media-room/world-leaders-make-historic-commitments-provide-equal-access-vaccines-all|archive-date=6 June 2020|url-status=live}}</ref>သြန်ဒါန် ဂၠိုင်အိုတ် ၁.၆ ဗဳလဳယာန် နူကဵု The Gates Foundation<ref>{{Cite press release |publisher=The Bill & Melinda Gates Foundation|via=PR Newswire|title=Bill & Melinda Gates Foundation pledges {{US$|1.6}}{{nbsp}}billion to Gavi, the Vaccine Alliance, to protect the next generation with lifesaving vaccines|url=https://www.prnewswire.com/news-releases/bill--melinda-gates-foundation-pledges-1-6-billion-to-gavi-the-vaccine-alliance-to-protect-the-next-generation-with-lifesaving-vaccines-301070878.html|access-date=2020-06-04|date=2020-06-04|archive-url=https://web.archive.org/web/20200604165907/https://www.prnewswire.com/news-releases/bill--melinda-gates-foundation-pledges-1-6-billion-to-gavi-the-vaccine-alliance-to-protect-the-next-generation-with-lifesaving-vaccines-301070878.html|archive-date=4 June 2020|url-status=live}}</ref> ကေုာံ သြန်ပံင်ဗြိတိန် ၃၃၀ မဳလဳယာန် ဇၟာပ်သၞာံ ပွိုင် မသုန်သၞာံ နူကဵု အလဵုအသဳဗြိတိန် (မတုပ်သၟဟ်ကဵု ဒဝ်လာအမေရိကာန် ၂.၁ ဗဳလဳယာန် ပ္ဍဲ ဂျောန် ၂၀၂၀)။<ref name=gavi-summit/>

ပ္ဍဲဒဳဇြေမ်ဗါ ဂှ် နကဵု Gates Foundation ဆက်ကဵုဒါန် သြန်ဒဝ်လာ ၂၅၀ မဳလဳယာန်ပၠန် သွက်ဂွံကဵု ကပေါတ်စွမ်ကဝ်ဝိဒ်-၁၉၊ လွဳယဲ ကေုာံ ဝက်သိန် သွက်ဍုင်ဒိုက်ဂတ် ပ္ဍဲသၞာံ ၂၀၂၁ တုဲ သြန်ဗွဝ်သီုဖအိုတ် ဒှ်အာ သြန်ဒဝ်လာအမေရိကာန် ၁.၇၅ ဗဳလဳယာန်။<ref name="gates12-10">{{cite news |first1=Haley | last1=Yamada |first2=Jon | last2=Schlosberg |first3=Seni | last3=Tienabeso |title=Bill and Melinda Gates Foundation announces $250 million COVID vaccine commitment |url=https://abcnews.go.com/Technology/bill-melinda-gates-foundation-announces-250-million-covid/story?id=74651890 |access-date=11 December 2020 |work=ABC News - Technology |date=10 December 2020}}</ref><ref name="gates12-9">{{cite news |title=Bill and Melinda Gates call for collaboration, continued innovation to overcome challenges of delivering COVID-19 scientific breakthroughs to the world |url=https://www.gatesfoundation.org/Media-Center/Press-Releases/2020/12/Bill-and-Melinda-Gates-call-for-collaboration-innovation-to-deliver-COVID-19-breakthroughs |access-date=11 December 2020 |work=Bill & Melinda Gates Foundation |date=9 December 2020}}</ref>

==ကမၠောန်==

[[File:The vaccine development process typically takes 10 to 15 years under a traditional timeline. Multiple regulatory pathways, such as Emergency Use Authorization, can be used to facilitate bringing a vaccine for COVID-19 to (49948301848).jpg|thumb|upright=1.4|လၟေင်အခိင် ဗွဲဓမ္မတာ မကၠောန်ပ္တိတ် ဝက်သိန်မွဲ နူစ စဵုကဵု ကမၠောန်တုဲဒှ်၊ မဒးကေတ်အခိင် အကြာ ၁၀ - ၁၅ သၞာံ]]
===ဒဒှ်အတိက်===
ကိုပ်ကၠာ ကပ်ယဲကဝ်ဝိဒ်-၁၉ ဟွံကတဵုဒှ်ဏီဂှ် ဝက်သိန် သွက်စဵုဒၞာယဲဂှ် ဟွံဂွံကၠောန်ပ္တိတ် သၞာံဗွဲမလအ်ရ။ တုဲပၠန် ဝက်သိန် ဒစဵုဒစး ကဝ်ရဝ်နာဝဳရုသ် သွက်မၞိဟ်ဂှ်လေဝ် ဟွံကေင် နွံကၠုင်လဝ်ရ။<ref name="gates2" /> ဆဂး ဝက်သိန် ဒစဵုဒစး ကဝ်ရဝ်နာဝဳရုသ် သွက်တိရစ္ဆာန်ဂှ် ကေင်ပ္တိတ်လဝ်နွံ မပ္တံကဵု သၞာံ ၂၀၀၃ သွက်ဂစေံ၊ ကၠဵု ကေုာံ ဗ္ဂဲ။<ref>{{cite journal|vauthors=Cavanagh D|date=December 2003|title=Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus|journal=Avian Pathology|volume=32|issue=6|pages=567–82|doi=10.1080/03079450310001621198|pmc=7154303|pmid=14676007|doi-access=free}}</ref> တုဲပၠန် ဝိက်သိန် မဒစဵုဒစး ဝဳရုသ်ကဝ်ရဝ်နာ ဗဳဇမတုပ် မပကဵု ညံင်မၞိဟ်ဂွံဒှ်ယဲ သာ(SARS) ကေုာံ ယဲမာ(MERS)ကေင်နွံကၠုင်လဝ်ကီုရ။ ဝက်သိန် ဒစဵုဒစး ယဲသာ<ref>{{cite journal|display-authors=6|vauthors=Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD, Bellini WJ, Barratt-Boyes S, Gambotto A|date=December 2003|title=Effects of a SARS-associated coronavirus vaccine in monkeys|journal=Lancet|volume=362|issue=9399|pages=1895–96|doi=10.1016/S0140-6736(03)14962-8|pmc=7112457|pmid=14667748}}</ref> ကဵု ယဲမာ<ref>{{cite journal|display-authors=6|vauthors=Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, AlHajri F, Osterhaus AD, Haagmans BL, Gambotto A|date=October 2014|title=Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice|journal=Vaccine|volume=32|issue=45|pages=5975–82|doi=10.1016/j.vaccine.2014.08.058|pmc=7115510|pmid=25192975}}</ref>ဂှ်လေဝ် ဟွံကေင်စမ်လဝ် မၞိဟ် ဆစမ်လဝ် ကဵုတိရစ္ဆာန်သၟးရ။

အတိုင်လိက်မပ္တိတ်လဝ်မ္ဂး ပ္ဍဲသၞာံ ၂၀၀၅ ကဵု ၂၀၀၆ မ္ဂး သွက်ဂွံကၠောန်ပ္တိတ် ဝက်သိန် ကေုာံ ဂဥုဲလွဳယဲသာဂှ် ဒှ်လဝ် အရာကိစ္စဇၞော် သၟိင်ဍုင်တအ်ကီုရ။<ref name="PMID 15655773">{{cite journal|display-authors=6|vauthors=Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD, Coccia JA, Graziano RF, Srinivasan M, Lowy I, Finberg RW, Subbarao K, Vogel L, Somasundaran M, Luzuriaga K, Sullivan JL, Ambrosino DM|date=February 2005|title=Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice|journal=The Journal of Infectious Diseases|volume=191|issue=4|pages=507–14|doi=10.1086/427242|pmc=7110081|pmid=15655773}}</ref><ref name="PMID 15885812">{{cite journal|display-authors=6|vauthors=Tripp RA, Haynes LM, Moore D, Anderson B, Tamin A, Harcourt BH, Jones LP, Yilla M, Babcock GJ, Greenough T, Ambrosino DM, Alvarez R, Callaway J, Cavitt S, Kamrud K, Alterson H, Smith J, Harcourt JL, Miao C, Razdan R, Comer JA, Rollin PE, Ksiazek TG, Sanchez A, Rota PA, Bellini WJ, Anderson LJ|date=September 2005|title=Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins|journal=Journal of Virological Methods|volume=128|issue=1–2|pages=21–28|doi=10.1016/j.jviromet.2005.03.021|pmc=7112802|pmid=15885812}}</ref><ref name="PMID 16453264">{{cite journal|display-authors=6|vauthors=Roberts A, Thomas WD, Guarner J, Lamirande EW, Babcock GJ, Greenough TC, Vogel L, Hayes N, Sullivan JL, Zaki S, Subbarao K, Ambrosino DM|date=March 2006|title=Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters|journal=The Journal of Infectious Diseases|volume=193|issue=5|pages=685–92|doi=10.1086/500143|pmc=7109703|pmid=16453264}}</ref>ပ္ဍဲသၞာံ ၂၀၂၀ ဂှ် ဂဥုဲ ကေုာံ ဝက်သိန် သွက်ဂွံလွဳ ကေုာံ သွက်စဵုဒၞာ ယဲသာ ပ္ဍဲမၞိဟ် မကၠောန်ကမၠောန်ဇေတ်တ်ဂှ် ဟွံကလိဂွံဏီရ။<ref name="JiangFutureVirology">{{cite journal|vauthors=Jiang S, Lu L, Du L|date=January 2013|title=Development of SARS vaccines and therapeutics is still needed|journal=Future Virology|volume=8|issue=1|pages=1–2|doi=10.2217/fvl.12.126|pmc=7079997|pmid=32201503}}</ref><ref>{{cite web|date=5 March 2020|title=SARS (severe acute respiratory syndrome)|url=https://www.nhs.uk/conditions/sars/|url-status=live|archive-url=https://web.archive.org/web/20200309174230/https://www.nhs.uk/conditions/sars/|archive-date=9 March 2020|access-date=31 January 2020|publisher=[[National Health Service]]}}</ref>

တုဲပၠန် ဝက်သိန် စဵုဒၞာယဲမာလေဝ် ဟွံမဲဏီကီုရ။<ref>{{cite journal|last1=Shehata|first1=Mahmoud M.|last2=Gomaa|first2=Mokhtar R.|last3=Ali|first3=Mohamed A.|last4=Kayali|first4=Ghazi|date=January 2016|title=Middle East respiratory syndrome coronavirus: a comprehensive review|journal=Frontiers of Medicine|volume=10|issue=2|pages=120–36|doi=10.1007/s11684-016-0430-6|pmc=7089261|pmid=26791756|name-list-style=vanc}}</ref> ကာလ ယဲမာကတဵုဒှ်ဂှ် တင်ဂၞင်သုတေသန မပလဝ် ပ္ဍဲအခိင်ယဲသာဂှ် ဒှ်အထံက်အရီုရောင် သွက််ဂွံကၠောန်ဗဒှ် ဝက်သိန်ရောင်ဂှ် စၟဳကေတ်လဝ်ကီုရ။<ref name="JiangFutureVirology" /><ref name="Butler3oct2013">{{cite journal|vauthors=Butler D|date=October 2012|title=SARS veterans tackle coronavirus|journal=Nature|volume=490|issue=7418|page=20|bibcode=2012Natur.490...20B|doi=10.1038/490020a|pmid=23038444|doi-access=free}}</ref> ၜိုတ်ဂိတုမာတ် ၂၀၂၀ ဂှ် ဝက်သိန်ယဲမာလဵုမွဲလေဝ် ဟွံစိုပ်ကဆံင် ကာလစွမ်ပထမ သွက်ဂွံစမ်မၞိဟ်ဏီ၊<ref>{{cite journal|display-authors=6|vauthors=Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh MD, Lamarre C, Zaidi FI, Boyer J, Kudchodkar SB, Jeong M, Darden JM, Park YK, Scott PT, Remigio C, Parikh AP, Wise MC, Patel A, Duperret EK, Kim KY, Choi H, White S, Bagarazzi M, May JM, Kane D, Lee H, Kobinger G, Michael NL, Weiner DB, Thomas SJ, Maslow JN|date=September 2019|title=Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial|journal=The Lancet. Infectious Diseases|volume=19|issue=9|pages=1013–22|doi=10.1016/S1473-3099(19)30266-X|pmc=7185789|pmid=31351922|doi-access=free}}</ref> တုဲပၠန် ဂဥုဲတၞဟ်ပိဂှ် ဒှ်အခိင်အဃောမကၠောန်ဗဒှ် ဇၞော်ပၟဝ်ဒၟံင်၊ ဂဥုဲတအ်ဂှ် ChAdOx1-MERS, BVRS-GamVac ကေုာံ MVA-MERS-S တအ်ရ။<ref>{{cite journal|vauthors=Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS|year=2019|title=Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus|journal=Frontiers in Microbiology|volume=10|page=1781|doi=10.3389/fmicb.2019.01781|pmc=6688523|pmid=31428074}}</ref>

===ကမၠောန် အလန်ကိုပ်ကၠာ ===
ကြဴနူ မဂွံတီကေတ် ကဝ်ရဝ်နာဝဳရုသ် ကၞာတ်ကၠောအ်မၞိဟ် ပ္ဍဲ ဒဳဇြေမ်ဗါ ၂၀၁၉၊<ref name="who-time">{{Cite web|date=27 April 2020|title=World Health Organization timeline – COVID-19|url=https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19|url-status=live|archive-url=https://web.archive.org/web/20200429012212/https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19|archive-date=29 April 2020|access-date=2 May 2020|publisher=World Health Organization}}</ref>သဏ္ဌာန်ဗဳဇ ကဝ်ဝိဒ်-၁၉ ဂှ် ဗၟံက်ထ္ၜးမာန် ပ္ဍဲကဵု ၁၁ ဇာန်နဝါရဳ ၂၀၂၀တုဲ ဂကောံမၞိဟ်ဂၠးတိ လလောင်တြး သွက်ဂွံပလေဝ်စ ယဲကမၠောအ်ကမၞာန်တုဲ သ္ဒးကၠောန်ဗဒှ် ဝက်သိန် သွက်ဂွံ ဒစဵုဒစးယဲဏအ်ရောင်။<ref name="thanh" /><ref name="gates1" /><ref name="Fauci">{{cite journal|vauthors=Fauci AS, Lane HC, Redfield RR|date=March 2020|title=Covid-19: Navigating the uncharted|journal=The New England Journal of Medicine|volume=382|issue=13|pages=1268–69|doi=10.1056/nejme2002387|pmc=7121221|pmid=32109011}}</ref>

ၜိုတ် ဂိတုဖေဖဝ်ဝါရဳ ၂၀၂၀ နကဵု ဂကောံထတ်ယုက်ဂၠးကဝ်ဟီု၊ ဝက်သိန် ဒစဵုဒစး ယဲသာ၂ (SARS-CoV-2) (အခိင်ဂှ် ကော်စ ယဲသာ၂) အပ္ဍဲ ပွိုင် ၁၈ ဂိတုဏအ် ကလိဂွံဟွံမာန်။<ref>{{cite web|last1=Grenfell|first1=Rob|last2=Drew|first2=Trevor|date=14 February 2020|title=Here's why the WHO says a coronavirus vaccine is 18 months away|url=https://theconversation.com/heres-why-the-who-says-a-coronavirus-vaccine-is-18-months-away-131213|access-date=11 November 2020|website=Business Insider|name-list-style=vanc}}</ref> ပ္ဍဲသၞာံ ၂၀၂၀ လပါ်စဂှ် လၟိဟ်မၞိဟ်စမၠောအ် ယဲဝဝ်ဝိဒ်-၁၉ ဂှ် ဂၠိုင်ကၠုင်တုဲ ဂကောံသၟိင်ဍုင်ဂမၠိုင် ကေုာံ ဂကောံထတ်ယုက်ဂၠးကဝ်တအ် ချပ်ဂၞန်ရေင်သကအ် ညံင်သဂွံ ဝက်သိန် နကဵုဗွဲပရဟ်မာန်ဂှ် ဒးကၠောန်ရ။<ref name="who-accel">{{Cite web|date=27 April 2020|title=Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine|url=https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-accelerating-a-safe-and-effective-covid-19-vaccine|url-status=live|archive-url=https://web.archive.org/web/20200430185550/https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-accelerating-a-safe-and-effective-covid-19-vaccine|archive-date=30 April 2020|access-date=2 May 2020|publisher=World Health Organization|quote=It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. [The] WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.}}</ref>

ပ္ဍဲဂိတုဨပြဳ ၂၀၂၀ ဂှ် နကဵု ဂကောံထတ်ယုက်ဂၠးကဝ် တော်ကေတ် သွက်ဂွံကၠောန်ပ္တိတ် ဝက်သိန်ဂှ် ဒးစကာသြန် ဒဝ်လာအမေရိကာန် ၈ ဗဳလဳယာန်။<ref name="who-accel" />

ၜိုတ်ဂိတု ဨပြဳ ၂၀၂၀ "ကမ္မဏဳ ကေုာံ အေန်သတဳကျုတ် ကြပ်ပေင် ၈၀ နူကဵု ၁၉ ရးနိဂီု" ဂှ် ကၠောန်ဒၟံင် သွက်ကလိဂွံ ဝက်သိန်ရ။<ref name="cssa">{{cite news|last1=Schmidt|first1=Charles|date=1 June 2020|title=Genetic Engineering Could Make a COVID-19 Vaccine in Months Rather Than Years|work=Scientific American|url=https://www.scientificamerican.com/article/genetic-engineering-could-make-a-covid-19-vaccine-in-months-rather-than-years1/|url-status=live|access-date=26 August 2020|archive-url=https://web.archive.org/web/20201011084737/https://www.scientificamerican.com/article/genetic-engineering-could-make-a-covid-19-vaccine-in-months-rather-than-years1//|archive-date=11 October 2020|name-list-style=vanc}}</ref> ပ္ဍဲကဵု ဂိတုဨပြဳဂှ်ရ CEPI တော်ကေတ် လၟောဝ်ဝက်သိန်သီုဖအိုတ်ဂှ် ၜိုတ်တြဴဂှ် နကဵုဂကောံပံင်ကောံဂၠးကဝ် ရုဲစှ် သွက်ဂွံကၠောန် ကာလစွမ်ဒုတိယ-တတိယ၊ ဂွံဂွံ လာင်ဇြေန် ဂွံကလိဂွံဇမၞးမာန်ဂှ် အောန်အိုတ် ဒးစကာသြန် အမေရိကာန်ဒဝ်လာ ၂ ဗဳလဳယာန်။<ref name="thanh2" /><ref name="yamey" /><ref name="gates2" /> သမ္ၚေဝ်တၞဟ်တအ် ညာတ်ကေတ် လၟောဝ်ဝက်သိန် ၁၀ နွံပၟိက် သွက်ဂွံဇၞော်ပၟဝ် ကိုပ်ကၠာဟွံဂွံစိုပ် ကဆံင်လက္ကရဴအိုတ် သွက်ကလိဂွံလာင်ဇြေန်ရ။<ref name="gates2" />

==ဝက်သိန်ဂမၠိုင်==
စိုပ် ၂၁ ဒဳဇြေမ်ဗါ ဂှ် ရးနိဂီုဂမၠိုင် ကေုာံ ကၟိန်ဍုင်ပံင်ကောံဥရောပ (အဳယူ)<ref name="eu vac" /> ကဵုအခေါင် ကေုာံ ပဒတန် ဝက်သေန် တဝ်ဇြိနမေရန် (tozinameran) ဗွဲမဂၠိုင် ကော်စ ဖရိဇြေရ်-ဗဳသြတေက် (Pfizer–BioNTech vaccine)။ ဍုင်ဗာရိုန် (Bahrain) ကဵု ဍုင်ပံင်ကောံအာရာပ် ဣမိရာတ် (United Arab Emirates) ပဒတန် ကဵုအခေါင်သွံ ဗွဲပရဟ် ကု BBIBP-CorV မကၠောန်ပ္တိတ် နူကဵု သိနဝ်ဖာမ် (Sinopharm) မဒှ်ဂကောံပ္တိတ်ဂဥုဲကြုက်ရ။<ref name="bna">{{cite news |title=Bahrain second in the world to approve the Pfizer/BioNTech Covid-19 vaccine |url=https://www.bna.bh/en/news?cms=q8FmFJgiscL2fwIzON1%2BDteRtB2wfPWh%2FOmYUjt6ApY%3D |access-date=9 December 2020 |publisher=Bahrain News Agency |date=4 December 2020}}</ref><ref name="uae">{{Cite news|title=UAE: Ministry of Health announces 86 per cent vaccine efficacy|url=https://gulfnews.com/uae/health/uae-ministry-of-health-announces-86-per-cent-vaccine-efficacy-1.1607490555571|access-date=9 December 2020|work=Gulf News }}</ref>ဒဳဇြေမ်ဗါ ၁၆ ဂှ် နကဵု ကၟိန်ဍုင်ဨကရာဇ်ယူကေ မၞိဟ်ဂွံထ္ပက် ဝက်သိန် ၁၃၈,၀၀၀ တၠ မဒှ်သတ္တဟကိုပ်ကၠာအိုတ် မစထ္ပက်ဝက်သိန်ဂှ်ရ။<ref name="graun-138">{{cite news|last=Campbell|first=Denis|date=16 December 2020|title=138,000 people in UK receive Covid vaccine in first week|newspaper=The Guardian|url=https://www.theguardian.com/world/2020/dec/16/138000-people-in-uk-have-received-covid-vaccine}}</ref> ဒဳဇြေမ်ဗါ ၁၁၊ ၂၀၂၀ ဂှ် နကဵု ရးနိဂီုပံင်ကောံအမေရိကာန် ကဵုအခေါင် ပဒတန် ဗွဲပရဟ် ကုတဝ်ဇြိနမေရန်။<ref name="thomas">{{Cite news|last1=Thomas|first1=Katie|last2=LaFraniere|first2=Sharon|last3=Weiland|first3=Noah|last4=Goodnough|first4=Abby|last5=Haberman|first5=Maggie|date=12 December 2020|title=F.D.A. Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away|work=[[The New York Times]]|url=https://www.nytimes.com/2020/12/11/health/pfizer-vaccine-authorized.html|access-date=12 December 2020|name-list-style=vanc}}</ref> သတ္တာဟဂတဂှ် ညးတအ် ပဒတန် ကု mRNA-1273 မကၠောန်ပ္တိတ် နူကဵု မဝ်ဒေရ်နာဝိသိန် (Moderna vaccine)ရ။<ref name="FDA PR 20201218" /><ref name="CDC ACIP Moderna COVID-19 Vaccine">{{cite journal|last1=Oliver|first1=Sara E.|last2=Gargano|first2=Julia W.|last3=Marin|first3=Mona|last4=Wallace|first4=Megan|last5=Curran|first5=Kathryn G.|last6=Chamberland|first6=Mary|last7=McClung|first7=Nancy|last8=Campos-Outcalt|first8=Doug|last9=Morgan|first9=Rebecca L.|last10=Mbaeyi|first10=Sarah|last11=Romero|first11=José R.|display-authors=6|date=December 2020|title=The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020|url=https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm695152e1-H.pdf|journal=MMWR. Morbidity and Mortality Weekly Report|volume=69|issue=5152|doi=10.15585/mmwr.mm695152e1|first12=H. Keipp|last13=Lee|last12=Talbot|first15=Kathleen|last15=Dooling|first14=Beth P.|last14=Bell|first13=Grace M.|pages=1653–1656|name-list-style=vanc}}</ref><ref name="CNBC 20201219">{{cite news|last1=Lovelace Jr.|first1=Berkeley|date=19 December 2020|title=FDA approves second Covid vaccine for emergency use as it clears Moderna's for U.S. distribution|publisher=CNBC|url=https://www.cnbc.com/2020/12/18/moderna-covid-vaccine-approved-fda-for-emergency-use.html|access-date=19 December 2020|name-list-style=vanc}}</ref>

ဝက်သိန်မွဲမွဲ ကၠောန်လဝ်တုဲ ဒးစမ်ၜတ် ပိကဆံင်၊ ညးကော်စ ကာလစွမ်ပထမ၊ ကာလစွမ်ဒုတိယ၊ ကေုာံ ကာလစွမ်တတိယ။ ကာလစွမ်ပထမဂှ် စမ်ရံင် ဂဥုဲဂှ် ကဵုအန္တရာယ် ကုမၞိဟ်မာန်ဟွံမာန် ကေုာံ မွဲသွုင်မ္ဂး ဂလိုင်လဵုဂွံစုတ်ရ။ ပ္ဍဲကာလဂှ်မ္ဂး ညးစမ် မၞိဟ်ပရေင်ထတ်ယုက်ထတ်တ် လၟိဟ်ၜိုတ် ၜါပိဒါဇြေန် (ၜိုတ် ပိစှ်ော)။ ကာလစွမ်ဒုတိယဂှ် အတိုင်သွဟ်မကလိဂွံ နူကဵုကာလစွမ်ပထမဂှ် ပညဳပညပ် ပလေဝ်တုဲ ဆက်စမ် မၞိဟ်မဂၠိုင်ကဵုကၠံ (သၟဝ်လ္ၚီ)။<ref name="Vaccines.gov">{{cite web |title=Vaccine Safety – Vaccines |url=https://www.vaccines.gov/basics/safety |website=vaccines.gov |publisher=US Department of Health and Human Services |access-date=13 April 2020 |archive-url=https://web.archive.org/web/20200422073442/https://www.vaccines.gov/basics/safety |archive-date=22 April 2020 |url-status=live }}</ref><ref name="fda-ddp">{{cite web |title=The drug development process |url=https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process |publisher=U.S. [[Food and Drug Administration]] (FDA) |access-date=12 April 2020 |date=4 January 2018 |archive-url=https://web.archive.org/web/20200222182002/https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process |archive-date=22 February 2020 |url-status=live }}</ref>ကာလစွမ် ပထမ-ဒုတိယ ဂှ် စမ်မဆေင်ကဵု ပရေင်ဂီုကၠီု ကေုာံ ဒြဟတ်အိမ်မုန် ဗွဲမဂၠိုင် မစမ် အစောမ်သတ္တိဂဥုဲ ကေုာံ အရာမကတဵုဒှ်မာန် မသ္ၚေဝ်ဂၠေပ် ဗွဲမချိုတ်ပၠိုတ်ရ။<ref name=fda-ddp/>ကာလစွမ်တတိယဂှ်မ္ဂး ဒးစမ်ၜတ် မၞိဟ်ဂၠိုင်ဂၠိုင် နကဵုမၞိဟ်နာနာသာ်၊ မၞိဟ်အာယုက်ဇၞော်၊ မၞိဟ်အာယုက်ဍောတ်၊ မၞိဟ်ပရေင်ထတ်ယုက် ဍိုန်လျ၊ မၞိဟ်ပရေင်ထတ်ယုက်ခိုဟ်၊ တုဲပၠန် မၞိဟ်သွက်ဂွံၜတ်ကၞာတ် မကော်ဂး control group၊ ဝက်သိန်ၜိုတ်လဵု ကၠောန်ကမၠောန် ပ္ဍဲအရာဒစဵုဒစး ယဲဂှ်ရ။<ref name=Vaccines.gov/><ref name=fda-ddp/> သွဟ်ပွံက်ဝက်သိန် ဂလိုင်လဵုဂီုကၠီု၊ ဂလိုင်လဵုမကၠောန်ကမၠောန် ကေုာံ စကာ နဒဒှ် ဂဥုဲဂွံ ဟွံဂွံတအ်ဂှ် ဒုင်သဇိုင် ကုသွဟ် နူကဵုကာလစွမ်တတိယဏအ်ရ။<ref name=cohen6-19/><ref name="cdc-eff">{{Cite web|title=How flu vaccine effectiveness and efficacy are measured|url=https://www.cdc.gov/flu/vaccines-work/effectivenessqa.htm?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fflu%2Fprofessionals%2Fvaccination%2Feffectivenessqa.htm|date=29 January 2016|publisher=Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, US Department of Health and Human Services|access-date=6 May 2020|archive-date=7 May 2020|archive-url=https://web.archive.org/web/20200507083203/https://www.cdc.gov/flu/vaccines-work/effectivenessqa.htm?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fflu%2Fprofessionals%2Fvaccination%2Feffectivenessqa.htm|url-status=live}}</ref><ref>{{Cite web|title=Principles of epidemiology, Section 8: Concepts of disease occurrence|url=https://www.cdc.gov/csels/dsepd/ss1978/lesson1/section8.html|date=18 May 2012|publisher=Centers for Disease Control and Prevention, Center for Surveillance, Epidemiology, and Laboratory Services, US Department of Health and Human Services|access-date=6 May 2020|archive-url=https://web.archive.org/web/20200406212227/https://www.cdc.gov/csels/dsepd/ss1978/lesson1/section8.html|archive-date=6 April 2020|url-status=live}}</ref>

===ဝက်သိန်ဂမၠိုင် မဂွံလဝ် အခေါင် ကေုာံ ဒတန်===
{| class="wikitable sortable"
|+ဝက်သိန်ဂမၠိုင် မဂွံလဝ် အခေါင် သွက်ကာပရဟ် ဟွံသေင်မ္ဂး ဒတန် သွက်ဂွံစကာ <br>Vaccines authorized for emergency use or approved for full use
|-
!လၟောဝ်ဝက်သိန်ဂမၠိုင် <br>ညးမကၠောန် ကေုာံ ညးမဒုင်ပစ္စဲ<br>Vaccine candidates,<br />developers, and sponsors
!ကွတ်<br>Technology
!ကာလစွမ် လၟုဟ်<br>Current phase (participants)<br />design
!ကာလစွမ် မစိုပ်ဒတုဲ (ညးမပါလုပ်ဂမၠိုင်)<br>မကၠောန်ကမၠောန် ပ္ဍဲအိမ်မုန်<br>Completed phase{{efn-la|Latest Phase with published results.}} (participants)<br />Immune response
!မကဵုအခေါင်စကာ နဒဒှ် ကာတၟေင် <br>Emergency use authorization
!ဍုင်မကဵုအခေါင် ပလဝ်ဒတန် <br>Full authorization
|- valign="top"
|'''[[Ad5-nCoV]]'''<br />[[CanSino Biologics]], Beijing Institute of Biotechnology of the [[Academy of Military Medical Sciences]], {{efn-la|name="Ad5-nCoV-manufacture"|Manufacturing partnership with the [[National Research Council (Canada)|National Research Council of Canada]] and Canadian Center for Vaccinology, [[Halifax, Nova Scotia|Halifax]], Nova Scotia<ref>{{Cite web|title=The National Research Council of Canada and CanSino Biologics Inc. announce collaboration to advance vaccine against COVID-19|url=https://www.canada.ca/en/national-research-council/news/2020/05/the-national-research-council-of-canada-and-cansino-biologics-inc-announce-collaboration-to-advance-vaccine-against-covid-19.html|publisher=National Research Council, Government of Canada|date=12 May 2020|access-date=22 May 2020|archive-url=https://web.archive.org/web/20200522153344/https://www.canada.ca/en/national-research-council/news/2020/05/the-national-research-council-of-canada-and-cansino-biologics-inc-announce-collaboration-to-advance-vaccine-against-covid-19.html|archive-date=22 May 2020|url-status=live}}</ref>}}
|[[Recombinant vaccine|Recombinant]] [[Adenoviridae|adenovirus]] [[Serotype|type]] 5 [[Viral vector|vector]]
|{{ClinicalStudyInfo|align=left|phase=3|participants=40,000|description=global multi-center, randomized, double-blind, placebo-controlled to evaluate efficacy, safety and immunogenicity.
|locations= China, Argentina, Chile,<ref>{{cite web |last1=Lazcano |first1=Patricio |title=Así funcionan las cuatro vacunas que se probarán en Chile |url=https://www.latercera.com/que-pasa/noticia/asi-funcionan-las-cuatro-vacunas-que-se-probaran-en-chile/AD22DRDA4REH5MRWGIAI7GQFSM/ |publisher=La Tercera |access-date=15 December 2020 |date=15 November 2020}}</ref> Mexico,<ref>{{cite web |last1=Martinez |first1=Ana Isabel |title=CanSino Biologics delivers COVID-19 vaccine to Mexico for late-stage trial |url=https://www.reuters.com/article/idUSKBN27J21V |publisher=Reuters |access-date=4 November 2020 |date=3 November 2020}}</ref> [[Pakistan]],<ref>{{cite web |last1=Ng |first1=Eric |title=China's CanSino trials Covid-19 vaccine in 'high disease burden' nations |url=https://www.scmp.com/business/companies/article/3107389/chinese-vaccine-developer-cansino-targets-high-disease-burden |work=South China Morning Post |access-date=4 November 2020 |date=28 October 2020}}</ref> Russia,<ref name="NCT04540419">{{cite web |title=Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04540419 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04540419 |date=13 November 2020 |access-date=17 November 2020}}</ref> [[Saudi Arabia]]<ref>{{cite web |last1=Nafisa |first1=Eltahir |title=CanSino to start Phase III trial of COVID-19 vaccine in Saudi |url=https://www.reuters.com/article/us-health-coronavirus-saudi-cansinobio/cansino-to-start-phase-iii-trial-of-covid-19-vaccine-in-saudi-idUSKCN2550L9 |publisher=Reuters |access-date=4 November 2020 |date=9 August 2020}}</ref><ref>{{cite web |last1=Gou |first1=Jinbo |title=Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above |url=https://clinicaltrials.gov/ct2/show/NCT04526990 |website=[[ClinicalTrials.gov]] |access-date=17 September 2020 |name-list-style=vanc |archive-date=18 September 2020 |archive-url=https://web.archive.org/web/20200918142722/https://clinicaltrials.gov/ct2/show/NCT04526990 |url-status=live }}</ref>
|duration=Mar. {{ndash}} Dec. 2020, China; Sep. 2020 {{ndash}} Dec. 2021, Pakistan; Sep. 2020 {{ndash}} Nov. 2020, Russia<ref name="NCT04540419" />
}}
|{{ClinicalStudyInfo|align=left|phase=2|participants=508|description=Neutralizing antibody and [[T cell]] responses<ref name="zhu7-20">{{cite journal | last1=Zhu | first1=Feng-Cai | last2=Guan | first2=Xu-Hua | last3=Li | first3=Yu-Hua | last4=Huang | first4=Jian-Ying | last5=Jiang | first5=Tao | last6=Hou | first6=Li-Hua | last7=Li | first7=Jing-Xin | last8=Yang | first8=Bei-Fang | last9=Wang | first9=Ling | last10=Wang | first10=Wen-Juan | last11=Wu | first11=Shi-Po | last12=Wang | first12=Zhao | last13=Wu | first13=Xiao-Hong | last14=Xu | first14=Jun-Jie | last15=Zhang | first15=Zhe | last16=Jia | first16=Si-Yue | last17=Wang | first17=Bu-Sen | last18=Hu | first18=Yi | last19=Liu | first19=Jing-Jing | last20=Zhang | first20=Jun | last21=Qian | first21=Xiao-Ai | last22=Li | first22=Qiong | last23=Pan | first23=Hong-Xing | last24=Jiang | first24=Hu-Dachuan | last25=Deng | first25=Peng | last26=Gou | first26=Jin-Bo | last27=Wang | first27=Xue-Wen | last28=Wang | first28=Xing-Huan | last29=Chen | first29=Wei | display-authors=6 | title=Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial | journal=Lancet | date=July 2020 | volume=396 | issue=10249 | pages=479–88 | issn=0140-6736 | doi=10.1016/s0140-6736(20)31605-6 | pmid=32702299 | doi-access=free | lay-url=https://blogs.sciencemag.org/pipeline/archives/2020/07/20/new-data-on-the-cansino-vaccine | name-list-style=vanc }}</ref>
}}
| '''Authorized'''<br />
*<small>China ''(early)''<ref>{{Cite web|title=CanSino's COVID-19 vaccine approved for military use in China|url=https://asia.nikkei.com/Business/Pharmaceuticals/CanSino-s-COVID-19-vaccine-approved-for-military-use-in-China|access-date=24 December 2020|website=Nikkei Asia}}</ref><ref>{{Cite news|title=More Than 2.7 Million People Have Gotten Vaccines: Covid-19 Tracker|publisher=Bloomberg L.P.|url=https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/|access-date=24 December 2020}}</ref></small>
|
|- valign="top"
|'''[[AZD1222]]'''<wbr/>{{efn-la|[[Serum Institute of India]] will be producing the ''ChAdOx1{{nbsp}}nCoV-19'' vaccine for India<ref>{{Cite news|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/astrazeneca-serum-institute-of-india-sign-licensing-deal-for-1-billion-doses-of-oxford-vaccine/articleshow/76202016.cms|title=AstraZeneca & Serum Institute of India sign licensing deal for 1 million doses of Oxford vaccine|work=The Economic Times|access-date=15 June 2020}}</ref> and other low and middle income countries.<ref>{{cite news |title=Covid-19 vaccine: Serum Institute signs up for 100 million doses of vaccines for India, low and middle-income countries |url=https://www.financialexpress.com/lifestyle/health/covid-19-vaccine-serum-institute-signs-up-for-100-million-doses-of-vaccines-for-india-low-and-middle-income-countries/2047884/ |work=The Financial Express |date=7 August 2020}}</ref>}}{{efn-la|Oxford name: ''ChAdOx1{{nbsp}}nCoV-19''. Manufacturing in Brazil to be carried out by [[Oswaldo Cruz Foundation]].<ref>{{cite news |last1=Walsh |first1=Nick |last2=Shelley |first2=Jo |last3=Duwe |first3=Eduardo |last4=Bonnett |first4=William |date=27 July 2020 |title=The world's hopes for a coronavirus vaccine may run in these health care workers' veins |url=https://edition.cnn.com/2020/07/27/americas/brazil-covid-19-sinovac-vaccine-intl/index.html |publisher=[[CNN]] |location=[[São Paulo]] |access-date=3 August 2020 |name-list-style=vanc |archive-date=3 August 2020 |archive-url=https://web.archive.org/web/20200803211040/https://edition.cnn.com/2020/07/27/americas/brazil-covid-19-sinovac-vaccine-intl/index.html |url-status=live }}</ref>}}<ref name="NCT04400838">{{cite web |title=Investigating a Vaccine Against COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04400838 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04400838 |date=26 May 2020 |access-date=14 July 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084750/https://clinicaltrials.gov/ct2/show/NCT04400838/ |url-status=live }}</ref><ref name="EudraCT-2020-001228-32">{{cite web |url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001228-32/GB |title=A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 |website=EU Clinical Trials Register |publisher=European Union |type=Registry |id=[[EudraCT]] 2020-001228-32 |date=21 April 2020 |access-date=3 August 2020 |archive-date=5 October 2020 |archive-url=https://web.archive.org/web/20201005201654/https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001228-32/GB |url-status=live }}</ref><ref name="ISRCTN89951424">{{cite journal |title=A Phase III study to investigate a vaccine against COVID-19 |website=ISRCTN |type=Registry |id=ISRCTN89951424 |doi=10.1186/ISRCTN89951424 |date=26 May 2020 |last1=O'Reilly |first1=Peter |name-list-style=vanc | doi-access=free }}</ref><br />[[University of Oxford]], [[AstraZeneca]]
|Modified [[chimpanzee]] [[Adenoviridae|adenovirus]] [[Viral vector|vector]] (ChAdOx1)
|{{ClinicalStudyInfo|align=left|phase=3|participants=30000|description=Interventional; [[randomized controlled trial|randomized, placebo-controlled study]] for efficacy, safety, and immunogenicity.<ref name="NCT04516746">{{cite web |title=A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04516746 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04383574 |date=12 May 2020 |access-date=26 August 2020 |archive-date=23 August 2020 |archive-url=https://web.archive.org/web/20200823061231/https://clinicaltrials.gov/ct2/show/NCT04516746 |url-status=live }}</ref>
Positive results from an interim analysis of four ongoing trials were announced on 23 November 2020 and published on 8 December 2020.<ref name="Voysey">{{cite web | url = https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext | title = Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK – The Lancet | access-date = 9 December 2020}}</ref> Overall efficacy was 70%, ranging from 62% to 90% with different dosing regimens, with a peer-reviewed safety profile.<ref name = "Voysey" />
|locations=Brazil (5,000),<ref>{{cite web |title=Trial of Oxford COVID-19 vaccine starts in Brazil |url=https://covid19vaccinetrial.co.uk/brazil-trial-launch |publisher=[[Jenner Institute]] |access-date=26 August 2020 |archive-date=9 September 2020 |archive-url=https://web.archive.org/web/20200909025948/https://covid19vaccinetrial.co.uk/brazil-trial-launch |url-status=live }}</ref> United Kingdom, India<ref>{{cite news |title=Oxford COVID-19 vaccine final trials will be held in these 17 hospitals in India |url=https://www.livemint.com/news/india/oxford-covid-19-vaccine-trials-will-be-held-in-these-17-hospitals-in-india-11597839519639.html |work=mint |date=19 August 2020 }}</ref>
|duration=May 2020{{snd}}Aug 2021
}}
<!-- |{{ClinicalStudyInfo|align=left|phase=2|endphase=3|participants=10260|description=Interventional; [[randomized controlled trial|randomized, placebo-controlled study]] for efficacy, safety, and immunogenicity}} -->
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=543|description=Spike-specific antibodies at day 28; [[neutralizing antibody|neutralizing antibodies]] after a [[booster dose]] at day 56<ref name="folegatti">{{cite journal |last1=Folegatti |first1=Pedro M |last2=Ewer |first2=Katie J |last3=Aley |first3=Parvinder K |last4=Angus |first4=Brian |last5=Becker |first5=Stephan |last6=Belij-Rammerstorfer |first6=Sandra |last7=Bellamy |first7=Duncan |last8=Bibi |first8=Sagida |last9=Bittaye |first9=Mustapha |last10=Clutterbuck |first10=Elizabeth A |last11=Dold |first11=Christina |last12=Faust |first12=Saul N |last13=Finn |first13=Adam |last14=Flaxman |first14=Amy L |last15=Hallis |first15=Bassam |last16=Heath |first16=Paul |last17=Jenkin |first17=Daniel |last18=Lazarus |first18=Rajeka |last19=Makinson |first19=Rebecca |last20=Minassian |first20=Angela M |last21=Pollock |first21=Katrina M |last22=Ramasamy |first22=Maheshi |last23=Robinson |first23=Hannah |last24=Snape |first24=Matthew |last25=Tarrant |first25=Richard |last26=Voysey |first26=Merryn |last27=Green |first27=Catherine |last28=Douglas |first28=Alexander D |last29=Hill |first29=Adrian V S |last30=Lambe |first30=Teresa |last31=Gilbert |first31=Sarah C |last32=Pollard |first32=Andrew J |display-authors=6 |author-link2=Katie Ewer |title=Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial |journal=Lancet |date=July 2020 |volume=396 |issue=10249 |pages=467–78 |doi=10.1016/S0140-6736(20)31604-4 |pmid=32702298 |pmc=7445431 |doi-access=free |lay-url=https://blogs.sciencemag.org/pipeline/archives/2020/07/20/new-data-on-the-oxford-az-vaccine |name-list-style=vanc }}</ref>}}
|'''Authorized'''<br />
{{smalldiv|1=
*UK<ref>{{cite web |title=Oxford University/AstraZeneca vaccine authorised by UK medicines regulator |url=https://www.gov.uk/government/news/oxford-universityastrazeneca-vaccine-authorised-by-uk-medicines-regulator |website=Gov.uk |publisher=Department of Health and Social Care|access-date=30 December 2020 |date=30 December 2020}}</ref>
*Argentina<ref>{{cite web |title=Argentine regulator approves AstraZeneca/Oxford COVID-19 vaccine |url=https://www.reuters.com/article/us-health-coronavirus-argentina-astrazen/argentine-regulator-approves-astrazeneca-oxford-covid-19-vaccine-astrazeneca-idUSKBN29421P |website=reuters.com |publisher=Reuters |access-date=30 December 2020 |date=30 December 2020}}</ref>
*India<ref>{{cite news |last1=Jamkhandikar |first1=Nigam Prusty, Shilpa |title=India drug regulator approves AstraZeneca COVID vaccine, country's first - sources |url=https://in.reuters.com/article/health-coronavirus-india-vaccine-idINKBN296290 |work=Reuters |date=1 January 2021 |language=en}}</ref><ref>{{cite news |last1=Gaurav |first1=Kunal |title=Govt's expert panel approves AstraZeneca/Oxford Covid-19 vaccine for emergency use |url=https://www.hindustantimes.com/india-news/india-s-drug-regulator-approves-astrazeneca-oxford-vaccine-sources/story-qtnJQQTBI5vR6QGrXdoBzN.html |work=Hindustan Times |date=1 January 2021 |language=en}}</ref>
*El Salvador<ref>{{cite news |last1=Staff |first1=Reuters |title=El Salvador greenlights AstraZeneca, Oxford University COVID-19 vaccine |url=https://www.reuters.com/article/us-health-coronavirus-el-salvador-vaccin/el-salvador-greenlights-astrazeneca-oxford-university-covid-19-vaccine-idINKBN2942HQ |work=Reuters |date=30 December 2020 |language=en}}</ref>
}}
|
|- valign="top"
|'''[[BBIBP-CorV]]'''<wbr /><ref name="ChiCTR2000034780">{{cite journal |last1=Chen |first1=Wei |last2=Al Kaabi |first2=Nawal |title=A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells) |journal=Chinese Clinical Trial Registry |date=18 July 2020 |url=http://www.chictr.org.cn/showprojen.aspx?proj=56651 |access-date=15 August 2020 |name-list-style=vanc }}</ref><br />[[China National Pharmaceutical Group|Sinopharm]]: Beijing Institute of Biological Products, Wuhan Institute of Biological Products
|[[Inactivated vaccine|Inactivated]] [[Severe acute respiratory syndrome coronavirus 2|SARS-CoV-2]] ([[vero cell]]s)
|{{ClinicalStudyInfo|align=left|phase=3|participants=48000|description=Randomized, double-blind, parallel placebo-controlled, to evaluate safety and protective efficacy.

Positive results from an interim analysis were announced by the UAE on 9 December 2020.<ref>{{cite web |title=UAE: Ministry of Health announces 86 per cent vaccine efficacy |url=https://gulfnews.com/uae/health/uae-ministry-of-health-announces-86-per-cent-vaccine-efficacy-1.1607490555571 |work=Gulf News |access-date=9 December 2020 }}</ref> Sinopharm's internal analysis indicated a 79% efficacy.<ref>{{Cite news|last1=Wee|first1=Sui-Lee|last2=Qin|first2=Amy|date=2020-12-30|title=A Chinese Covid-19 Vaccine Has Proved Effective, Its Maker Says|language=en-US|work=The New York Times|url=https://www.nytimes.com/2020/12/30/business/china-vaccine.html|access-date=2020-12-30|issn=0362-4331}}</ref>|locations=[[United Arab Emirates|UAE]], [[Bahrain]], [[Jordan]],<ref>{{cite web |last1=Yang |first1=Yunkai |title=A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above |url=https://clinicaltrials.gov/ct2/show/NCT04510207 |website=[[ClinicalTrials.gov]] |access-date=15 September 2020 |name-list-style=vanc |archive-date=14 September 2020 |archive-url=https://web.archive.org/web/20200914040138/https://clinicaltrials.gov/ct2/show/NCT04510207 |url-status=live }}</ref> [[Argentina]],<ref>{{cite web |title=Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19) |url=https://clinicaltrials.gov/ct2/show/NCT04560881?term=vaccine&cond=covid-19&draw=2&rank=3 |website=[[ClinicalTrials.gov]] |access-date=28 September 2020 }}</ref> [[Morocco]],<ref>{{cite web |title=A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells) |url=http://www.chictr.org.cn/showprojen.aspx?proj=62581 |website=chictr.org.cn |publisher=Chinese Clinical Trial Register (ChiCTR) |access-date=15 December 2020}}</ref> [[Peru]]<ref>{{Cite web|title=Bahrain allows Sinopharm COVID-19 vaccine candidate use in frontline workers|url=https://www.msn.com/en-au/lifestyle/wellbeing/bahrain-announces-emergency-approval-for-use-of-covid-19-vaccine-candidate/ar-BB1aEciR |access-date=3 November 2020|publisher=MSN|agency=Reuters}}</ref>|duration=Jul 2020 – Jul 2021}}

|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=320|description=Neutralizing antibodies at day 14 after 2 injections<ref>{{cite journal |vauthors=Xia S, Duan K, Zhang Y, Zhao D, et al. |title=Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials |journal=JAMA |date=13 August 2020 |volume=324 |issue=10 |pages=951–960 |doi=10.1001/jama.2020.15543 |pmid=32789505 |pmc=7426884 |doi-access=free }}</ref>
|locations=China

|duration=Apr 2020 – Jun 2020
}}
| 
| '''Authorized'''
{{smalldiv|1=
*[[United Arab Emirates|UAE]]<ref name="nyt-uae-wee-dec-12-2020">{{cite news |last1=Wee |first1=Sui-Lee |title=Chinese Covid-19 Vaccine Gets Key Push, but Doubts Swirl |url=https://www.nytimes.com/2020/12/09/business/china-coronavirus-vaccine-united-arab-emirates.html |access-date=12 December 2020 |work=[[The New York Times]] |date=9 December 2020}}</ref><ref>{{Cite web|title=Coronavirus: UAE authorises emergency use of vaccine for frontline workers|url=https://www.thenationalnews.com/uae/health/coronavirus-uae-authorises-emergency-use-of-vaccine-for-frontline-workers-1.1077680|access-date=24 November 2020|website=The National}}</ref>
*Bahrain
*China
}}
</small>
|- valign="top"
|'''[[CoronaVac]]'''<ref name="NCT04383574">{{cite web |title=Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19) (Renqiu) |url=https://clinicaltrials.gov/ct2/show/NCT04383574 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04383574 |date=12 May 2020 |access-date=14 July 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084809/https://clinicaltrials.gov/ct2/show/NCT04383574/ |url-status=live }}</ref><ref name="NCname= nct04456595=">{{cite web |url=https://clinicaltrials.gov/ct2/show/NCT04456595 |title=Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV) |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04456595 |date=2 July 2020 |access-date=3 August 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084811/https://clinicaltrials.gov/ct2/show/NCT04456595/ |url-status=live }}</ref><ref>{{cite journal |last1=PT. Bio Farma |title=A Phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-COV-2 inactivated vaccine in healthy adults aged 18–59 years in Indonesia |journal=Registri Penyakit Indonesia |date=10 August 2020 |url=https://www.ina-registry.org/index.php?act=registry_trial_detail&code_trial=16202009080721WXFM0YX |access-date=15 August 2020 }}</ref><br />[[Sinovac Biotech|Sinovac]]
|[[Inactivated vaccine|Inactivated]] [[Severe acute respiratory syndrome coronavirus 2|SARS-CoV-2]]
|{{ClinicalStudyInfo|align=left|phase=3|participants=33,620|description=Double-blind, randomized, placebo-controlled to evaluate efficacy and safety.

Positive results from an interim analysis were announced by Brazil on 23 December 2020 and Turkey on 24 December 2020.<ref>{{cite web |last1=Fonseca |first1=Pedro |title=Brazil institute says CoronaVac efficacy above 50%, but delays full results |url=https://www.reuters.com/article/us-health-coronavirus-sinovac-brazil/brazil-institute-says-coronavac-efficacy-above-50-but-delays-full-results-idUSKBN28X2CR |publisher=Reuters |access-date=28 December 2020 |date=24 December 2020}}</ref><ref>{{cite web |title=Turkish official says CoronaVac vaccine 91.25% effective |url=https://abcnews.go.com/Health/wireStory/turkish-official-coronavac-vaccine-9125-effective-74899577 |publisher=ABC News |agency=Associated Press |access-date=28 December 2020 }}</ref>
|locations=Brazil (15,000);<ref>{{Cite web |url=https://www.scmp.com/news/world/americas/article/3106177/tests-show-coronavirus-vaccine-chinas-sinovac-safe-says-brazils |title=Tests show coronavirus vaccine by China's Sinovac is safe, says Brazil's Butantan Institute |access-date=29 October 2020 |archive-date=29 October 2020 |archive-url=https://web.archive.org/web/20201029151527/https://www.scmp.com/news/world/americas/article/3106177/tests-show-coronavirus-vaccine-chinas-sinovac-safe-says-brazils |url-status=live }}</ref> Chile (3,000);<ref>{{Cite web |url=https://chilereports.cl/en/news/2020/08/04/chile-initiates-clinical-study-for-covid-19-vaccine |title=Chile initiates clinical study for COVID-19 vaccine |access-date=29 October 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011190302/https://chilereports.cl/en/news/2020/08/04/chile-initiates-clinical-study-for-covid-19-vaccine |url-status=live }}</ref> [[Indonesia]] (1,620); [[Turkey]] (13,000)<ref>{{cite web |title=Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated |url=https://clinicaltrials.gov/ct2/show/NCT04582344 |website=[[ClinicalTrials.gov]] |date=8 October 2020 |access-date=22 October 2020 |archive-date=20 October 2020 |archive-url=https://web.archive.org/web/20201020123218/https://clinicaltrials.gov/ct2/show/NCT04582344 |url-status=live }}</ref>
|duration=Jul 2020 – Oct 2021 in Brazil; Aug 2020 – Jan 2021 in Indonesia
}}
|{{ClinicalStudyInfo|align=left|phase=2|participants=600|description=Immunogenicity eliciting 92% seroconversion at lower dose and 98% at higher dose after 14 days<ref>{{cite journal |last1=Zhang |first1=Yanjun |last2=Zeng |first2=Gang |last3=Pan |first3=Hongxing |last4=Li |first4=Changgui |last5=Hu |first5=Yaling |last6=Chu |first6=Kai |last7=Han |first7=Weixiao |last8=Chen |first8=Zhen |last9=Tang |first9=Rong |last10=Yin |first10=Weidong |last11=Chen |first11=Xin |last12=Hu |first12=Yuansheng |last13=Liu |first13=Xiaoyong |last14=Jiang |first14=Congbing |last15=Li |first15=Jingxin |last16=Yang |first16=Minnan |last17=Song |first17=Yan |last18=Wang |first18=Xiangxi |last19=Gao |first19=Qiang |last20=Zhu |first20=Fengcai | display-authors=6 |title=Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial |journal=The Lancet Infectious Diseases |date=November 2020 |volume=0 |doi=10.1016/S1473-3099(20)30843-4 |pmid=33217362 |s2cid=227099817 | doi-access=free |name-list-style=vanc }}</ref>
|locations=China
|duration=May 2020 -
}}
| '''Authorized'''<br />
{{smalldiv|1=
*China''(early)''<ref>{{Cite news|title=China prepares large-scale rollout of domestically-produced coronavirus vaccines|url=https://www.theglobeandmail.com/world/article-china-prepares-large-scale-rollout-of-domestically-produced|date=6 December 2020|access-date=7 December 2020|work=The Globe and Mail|first=Huizhong | last=Wu }}</ref>
</small>
}}
| 
|- valign="top"
|'''[[Gam-COVID-Vac]]'''<br /> [[Gamaleya Research Institute of Epidemiology and Microbiology]];<br />[[Trade name]]: '''''Sputnik V'''''
|Non-[[Viral replication|replicating]] [[viral vector]] ([[Adenoviridae#Vaccines|adenovirus]])
|{{ClinicalStudyInfo|align=left|phase=3|participants=40,000|description=Randomized double-blind, placebo-controlled to evaluate efficacy, immunogenicity, and safety<ref>{{cite web |title=Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04530396?term=vaccine&cond=covid-19&draw=3 |website=ClinicalTrials.gov |access-date=11 September 2020 |archive-date=12 September 2020 |archive-url=https://web.archive.org/web/20200912231654/https://clinicaltrials.gov/ct2/show/NCT04530396?term=vaccine&cond=covid-19&draw=3 |url-status=live }}</ref>
|locations=Russia, Belarus<ref>{{cite news |title=Клинические исследования вакцины "Спутник V" в Беларуси начались раньше |url=https://www.belta.by/society/view/klinicheskie-issledovanija-vaktsiny-sputnik-v-v-belarusi-nachalis-ranshe-408737-2020/ |work=BELTA |date=29 September 2020 |language=ru}}</ref>, India<ref>{{cite news |last1=Kumar |first1=Shivani |title=Sputnik-V from Russia arrives in India for clinal trials |url=https://www.hindustantimes.com/india-news/sputnik-v-from-russia-arrives-in-india-for-clinal-trials/story-b8k3Ecncxw2RBTrIxOiqxO.html |work=Hindustan Times |date=1 December 2020 }}</ref><ref>{{cite news |title=Clinical trial: 17 volunteers given Russia's Sputnik V Covid-19 vaccine in Pune |url=https://indianexpress.com/article/india/clinical-trial-17-volunteers-given-russias-sputnik-v-covid-19-vaccine-in-pune-7094153/ |work=The Indian Express |date=6 December 2020 }}</ref>, Venezuela<ref>{{cite news |title=Sputnik V’s Clinical Trials in Venezuela: What We Do and Do Not Know |url=https://pulitzercenter.org/reporting/sputnik-vs-clinical-trials-venezuela-what-we-do-and-do-not-know-spanish |work=Pulitzer Center |date=5 November 2020 |language=en}}</ref>
|duration=Aug 2020 – May 2021
}}
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=76|description=[[Neutralizing antibody]] and [[T cell]] responses.<ref name="logunov">{{cite journal | last1=Logunov | first1=Denis Y | last2=Dolzhikova | first2=Inna V | last3=others | title=Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia | journal=The Lancet | year=2020 | volume=396 | issue=10255 | pages=887–97 | issn=0140-6736 | doi=10.1016/s0140-6736(20)31866-3 | pmid=32896291 | pmc=7471804 | s2cid=221472251 | doi-access=free | name-list-style=vanc }}</ref>
|locations=Russia
|duration=Jun 2020<ref name="logunov" /> - Sep 2020
}}
| '''Authorized'''<br />
{{smalldiv|1=
*Russia<ref name="burki">{{cite journal | vauthors = Burki TK | title = The Russian vaccine for COVID-19 | journal = The Lancet. Respiratory Medicine | volume = 8 | issue = 11 | pages = e85–e86 | date = November 2020 | pmid = 32896274 | doi = 10.1016/S2213-2600(20)30402-1 | url = https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30402-1/fulltext | doi-access = free }}</ref>
*Belarus<ref>{{cite news |title=Belarus registers Sputnik V vaccine, in first outside Russia - RDIF |url=https://www.reuters.com/article/us-health-coronavirus-vaccine-belarus/belarus-registers-sputnik-v-vaccine-in-first-outside-russia-rdif-idINKBN28V0ZG |access-date=22 December 2020 |publisher=Reuters |date=21 December 2020 }}</ref>
*Argentina<ref>{{cite news |title=Argentina has registered the Sputnik V vaccine based on Russian clinical trial data |url=https://sputnikvaccine.com/newsroom/pressreleases/argentina-has-registered-the-sputnik-v-vaccine-based-on-russian-clinical-trial-data-/ |access-date=1 January 2021 |work=sputnikvaccine.com |language=en}}</ref>
*Bolivia<ref>{{cite news |title=Ministerio de Salud de Bolivia - Bolivia y Rusia firman contrato para adquirir 5,2 millones de dosis de la vacuna Sputnik-V contra la COVID-19 |url=https://www.minsalud.gob.bo/5114-bolivia-y-rusia-firman-contrato-para-adquirir-5-2-millones-de-dosis-de-la-vacuna-sputnik-v-contra-el-covid-19 |access-date=1 January 2021 |work=www.minsalud.gob.bo}}</ref>
*Venezuela<ref>{{cite news |title=Venezuela to buy Sputnik V vaccine to vaccinate 10 mln people |url=https://tass.com/society/1241067 |work=TASS |date=29 December 2020 |language=en}}</ref><ref>{{cite news |title=Venezuela firma contrato para la adquisición de la vacuna rusa Sputnik V |url=https://lta.reuters.com/article/salud-coronavirus-venezuela-rusia-idLTAKBN2931X2 |work=Reuters |date=29 December 2020 |language=es}}</ref>
*Serbia<ref>{{cite news |title=Agencija odobrila uvoz ruske vakcine Sputnjik V u Srbiju |url=https://rs.n1info.com/vesti/agencija-odobrila-uvoz-ruske-vakcine-sputnjik-v-u-srbiju/ |work=N1 |date=31 December 2020 |language=sr-RS}}</ref>
}}
|
|- valign="top"
|'''[[mRNA-1273]]'''<wbr /><ref name="NCT04470427">{{cite web |title=A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04470427 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04470427 |date=14 July 2020 |access-date=27 July 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084833/https://clinicaltrials.gov/ct2/show/NCT04470427/ |url-status=live }}</ref><ref name="palca">{{cite news |last1=Palca |first1=Joe |title=COVID-19 vaccine candidate heads to widespread testing in U.S. |url=https://www.npr.org/sections/coronavirus-live-updates/2020/07/27/895672859/us-vaccine-candidate-heads-to-widespread-testing-in-people |access-date=27 July 2020 |publisher=NPR |date=27 July 2020 |name-list-style=vanc |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084836/https://www.npr.org/sections/coronavirus-live-updates/2020/07/27/895672859/us-vaccine-candidate-heads-to-widespread-testing-in-people/ |url-status=live }}</ref><br />[[Moderna]], [[National Institute of Allergy and Infectious Diseases|NIAID]], [[Biomedical Advanced Research and Development Authority|BARDA]]
|[[Solid lipid nanoparticle|Lipid nanoparticle]] dispersion containing [[modRNA]]
|{{ClinicalStudyInfo|align=left|phase=3|participants=30000|description=Interventional; randomized, placebo-controlled study for efficacy, safety, and immunogenicity.
Positive results from an interim analysis were announced on 15 November 2020.<ref>{{cite web |title=Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine |url=https://www.nih.gov/news-events/news-releases/promising-interim-results-clinical-trial-nih-moderna-covid-19-vaccine |website=National Institutes of Health (NIH) |date=15 November 2020}}</ref>
|locations=United States
|duration=Jul 2020{{snd}}Oct 2022
}}
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=720
|references=<ref>{{Cite journal|last=National Institute of Allergy and Infectious Diseases (NIAID)|date=3 December 2020|title=Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults|url=https://clinicaltrials.gov/ct2/show/NCT04283461}}</ref><ref>{{Cite web|title=Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older |url=https://clinicaltrials.gov/ct2/show/NCT04405076|access-date=19 December 2020|website=ClinicalTrials.gov }}</ref>
|description=Dose-dependent neutralizing antibody response on two-dose schedule; undetermined durability.<ref>{{cite journal | last1=Widge | first1=Alicia T. | last2=Rouphael | first2=Nadine G. | last3=Jackson | first3=Lisa A. | last4=Anderson | first4=Evan J. | last5=Roberts | first5=Paul C. | last6=Makhene | first6=Mamodikoe | last7=Chappell | first7=James D. | last8=Denison | first8=Mark R. | last9=Stevens | first9=Laura J. | last10=Pruijssers | first10=Andrea J. | last11=McDermott | first11=Adrian B. | last12=Flach | first12=Britta | last13=Lin | first13=Bob C. | last14=Doria-Rose | first14=Nicole A. | last15=O'Dell | first15=Sijy | last16=Schmidt | first16=Stephen D. | last17=Neuzil | first17=Kathleen M. | last18=Bennett | first18=Hamilton | last19=Leav | first19=Brett | last20=Makowski | first20=Mat | last21=Albert | first21=Jim | last22=Cross | first22=Kaitlyn | last23=Edara | first23=Venkata-Viswanadh | last24=Floyd | first24=Katharine | last25=Suthar | first25=Mehul S. | last26=Buchanan | first26=Wendy | last27=Luke | first27=Catherine J. | last28=Ledgerwood | first28=Julie E. | last29=Mascola | first29=John R. | last30=Graham | first30=Barney S. | last31=Beigel | first31=John H. | name-list-style=vanc | display-authors=6 | title=Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination | journal=New England Journal of Medicine | publisher=Massachusetts Medical Society | date=3 December 2020 | issn=0028-4793 | doi=10.1056/nejmc2032195 | pmid=33270381 | pmc=7727324 | doi-access=free }}</ref><ref name="jackson">{{cite journal |vauthors=Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson PA, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH |collaboration=mRNA-1273 Study Group |display-authors=6 |title=An mRNA Vaccine against SARS-CoV-2 – Preliminary Report |journal=New England Journal of Medicine |date=July 2020 |volume=383 |issue=20 |pages=1920–1931 |doi=10.1056/NEJMoa2022483 |doi-access=free |pmid=32663912 |pmc=7377258 |lay-url=https://www.statnews.com/2020/07/14/moderna-covid19-vaccine-first-data-show-spurs-immune-response/ }}</ref><ref name="jackson-app">{{cite journal |vauthors=Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson PA, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH |collaboration=mRNA-1273 Study Group |display-authors=6 |title=An mRNA Vaccine against SARS-CoV-2 – Preliminary Report Supplementary appendix |journal=New England Journal of Medicine |date=July 2020 |doi=10.1056/NEJMoa2022483 |doi-access=free |pmid=32663912 }}</ref>
|locations=United States
|duration=Mar 2020{{snd}}Nov 2021
}}
|'''Authorized'''<br />
{{smalldiv|1=
*USA<ref name="FDA PR 20201218">{{cite press release | title=FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine | website=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid | access-date=18 December 2020}}</ref><ref name="CDC ACIP Moderna COVID-19 Vaccine" />
*Canada<ref name="hc-moderna12-23">{{cite web |title=Regulatory Decision Summary – Moderna COVID-19 Vaccine – Health Canada |url=https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00736 |publisher=Health Canada, Government of Canada |access-date=23 December 2020 |date=23 December 2020}}</ref><ref name="hcapps" />}}
|
|- valign="top"
|'''[[Tozinameran]]'''<wbr /><ref name="hcreg">{{cite web|date=9 December 2020|title=Regulatory Decision Summary – Pfizer-BioNTech COVID-19 Vaccine|url=https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00730|access-date=9 December 2020|publisher=Health Canada, Government of Canada}}</ref><ref name="NCT04368728">{{cite web |title=Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults |url=https://clinicaltrials.gov/ct2/show/NCT04368728 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04368728 |date=30 April 2020 |access-date=14 July 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084828/https://clinicaltrials.gov/ct2/show/NCT04368728/ |url-status=live }}</ref><ref name="EudraCT-2020-001038-36">{{cite web |title=A Multi-site Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults |url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001038-36/DE |website=EU Clinical Trials Register |publisher=European Union |type=Registry |id=[[EudraCT]] 2020-001038-36 |date=14 April 2020 |access-date=22 April 2020 |archive-url=https://web.archive.org/web/20200422111024/https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001038-36/DE |archive-date=22 April 2020 |url-status=live}}</ref><br />[[BioNTech]], [[Pfizer]], [[Fosun Pharma]]
|[[modRNA]]
|{{ClinicalStudyInfo|align=left|phase=3|participants=43,448|description=Randomized, placebo-controlled|references=<ref>{{cite web |title=Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine |url=https://www.businesswire.com/news/home/20201210005703/en/ |publisher=Pfizer | via=Business Wire |access-date=11 December 2020}}</ref>

Positive results from an interim analysis were announced on 18 November 2020<ref>{{cite web |last1=Lovelace Jr. |first1=Berkeley |title=Pfizer says final data analysis shows Covid vaccine is 95% effective, plans to submit to FDA in days |url=https://www.cnbc.com/2020/11/18/coronavirus-pfizer-vaccine-is-95percent-effective-plans-to-submit-to-fda-in-days.html |publisher=CNBC |date=18 November 2020 |name-list-style=vanc}}</ref> and published on 10 December 2020 reporting an overall efficacy of 95%.<ref>{{cite web |title=Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in ''The New England Journal of Medicine'' |url=https://www.businesswire.com/news/home/20201210005703/en/ |publisher=Pfizer | via=Business Wire |access-date=11 December 2020}}</ref><ref>{{cite report| url=https://www.fda.gov/media/144337/download | title=FDA Review of Efficacy and Safety of Pfizer-BioNTech COVID-19 Vaccine Emergency Use Authorization Request | website=U.S. [[Food and Drug Administration]] (FDA) | date=10 December 2020 | access-date=11 December 2020}} {{PD-notice}}</ref>
|locations=Germany, United States
|duration=Jul{{nbsp}}2020 – Nov{{nbsp}}2020<ref>{{Cite news|title=Pfizer ends COVID-19 trial with 95% efficacy, to seek emergency-use authorization|url=https://www.reuters.com/article/health-coronavirus-vaccines-pfizer/pfizer-ends-covid-19-trial-with-95-efficacy-to-seek-emergency-use-authorization-idUSL4N2HZ3VS|first=Michael | last=Erman |access-date=18 November 2020|publisher=Reuters|date=18 November 2020}}</ref><ref name="NYT-20201120" />
}}

|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=45|description=Strong RBD-binding [[Immunoglobulin G|IgG]] and [[neutralizing antibody]] response peaked 7 days after a [[booster dose]], robust CD4+ and CD8+ [[T cell]] responses, undetermined durability<ref>{{cite news|last=Tiggle|first=Nick|title=Covid-19 vaccine: Allergy warning over new jab|url= https://www.bbc.co.uk/news/health-55244122 |date=9 December 2020|work=BBC News|access-date= 9 December 2020}}</ref><ref>{{cite journal |last1=Mulligan |first1=Mark J. |last2=Lyke |first2=Kirsten E. |last3=Kitchin |first3=Nicholas |last4=Absalon |first4=Judith |last5=Gurtman |first5=Alejandra |last6=Lockhart |first6=Stephen |last7=Neuzil |first7=Kathleen |last8=Raabe |first8=Vanessa |last9=Bailey |first9=Ruth |last10=Swanson |first10=Kena A. |last11=Li |first11=Ping |last12=Koury |first12=Kenneth |last13=Kalina |first13=Warren |last14=Cooper |first14=David |last15=Fontes-Garfias |first15=Camila |last16=Shi |first16=Pei-Yong |last17=Türeci |first17=Özlem |last18=Tompkins |first18=Kristin R. |last19=Walsh |first19=Edward E. |last20=Frenck |first20=Robert |last21=Falsey |first21=Ann R. |last22=Dormitzer |first22=Philip R. |last23=Gruber |first23=William C. |last24=Şahin |first24=Uğur |last25=Jansen |first25=Kathrin U. | display-authors=6 |title=Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults |doi-access=free |journal=Nature |pages=589–593 |doi=10.1038/s41586-020-2639-4 |date=October 2020 |volume=586 |issue=7830 |pmid=32785213 |s2cid=221126922 |name-list-style=vanc }}</ref>
|duration=May.{{nbsp}}2020 – }}
| '''Authorized'''<br />
{{smalldiv|1=
*UK<ref name="ukgov12-2">{{cite web |title=UK medicines regulator gives approval for first UK COVID-19 vaccine |url=https://www.gov.uk/government/news/uk-medicines-regulator-gives-approval-for-first-uk-covid-19-vaccine |publisher=Medicines and Healthcare Products Regulatory Agency, Government of the UK |access-date=2 December 2020 |date=2 December 2020}}</ref><ref name="MHRA 2020-12-08">{{cite web | title=Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine | website=Medicines & Healthcare products Regulatory Agency (MHRA) | date=8 December 2020 | url=https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/information-for-healthcare-professionals-on-pfizerbiontech-covid-19-vaccine | access-date=13 December 2020}}</ref><ref>{{cite web | title=Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine | website=Medicines & Healthcare products Regulatory Agency (MHRA) | date=3 December 2020 | url=https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/conditions-of-authorisation-for-pfizerbiontech-covid-19-vaccine | access-date=13 December 2020}}</ref>
*Bahrain<ref>{{cite web |title=Bahrain becomes second country to approve Pfizer COVID-19 vaccine |url=https://www.aljazeera.com/news/2020/12/4/bahrain-becomes-second-country-to-approve-pfizer-covid-19-vaccine |publisher=[[Al Jazeera]] |access-date=5 December 2020}}</ref>
*Canada<ref name=hcreg/><ref name="hcapps">{{cite web|date=9 December 2020|title=Drug and vaccine authorizations for COVID-19: List of applications received|url=https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization/applications.html|access-date=9 December 2020|publisher=Health Canada, Government of Canada}}</ref>
*USA<ref>{{cite press release | title=FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine | publisher=U.S. [[Food and Drug Administration]] (FDA) | date=11 December 2020 | url=https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19 | access-date=11 December 2020}} {{PD-notice}}</ref><ref>
{{cite web | title=Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet for Healthcare Providers | publisher=Pfizer | date=11 December 2020 | url=https://www.fda.gov/media/144413/download | format=PDF}}</ref>
*Mexico<ref>{{Cite news|date=12 December 2020|title=Mexico Approves Pfizer Vaccine for Emergency Use as Covid Surges|work=Bloomberg|url=https://www.bloomberg.com/news/articles/2020-12-12/mexico-approves-pfizer-vaccine-for-emergency-use-as-covid-surges|access-date=12 December 2020}}</ref>
*Kuwait<ref>{{cite web|access-date=15 December 2020|title=Kuwait authorizes emergency use of Pfizer-BioNTech COVID-19 vaccine|url=https://arab.news/427j9|date=13 December 2020|website=Arab News}}</ref>
*Singapore<ref>{{cite web|access-date=15 December 2020|title=Singapore approves use of Pfizer's COVID-19 vaccine|url=https://apnews.com/article/science-singapore-coronavirus-pandemic-lee-hsien-loong-coronavirus-vaccine-5bf8461b9d2d32ec08d56fcf5958317a|date=14 December 2020|website=AP NEWS}}</ref>
*Jordan<ref>{{cite web|access-date=15 December 2020|title=Jordan approves Pfizer-BioNTech Covid vaccine|url=https://www.france24.com/en/live-news/20201215-jordan-approves-pfizer-biontech-covid-vaccine|date=15 December 2020|publisher=France 24}}</ref>
*Oman<ref name="oman">{{Cite news|date=15 December 2020|title=Oman issues licence to import Pfizer BioNTech Covid vaccine – TV|publisher=Reuters|url=https://www.reuters.com/article/health-coronavirus-oman-vaccine-int-idUSKBN28P1RA|access-date=16 December 2020}}</ref>
*Costa Rica<ref name="costa">{{cite web|access-date=16 December 2020|title=Costa Rica authorizes Pfizer-BioNTech coronavirus vaccine|url=https://ticotimes.net/2020/12/16/costa-rica-authorizes-pfizer-biontech-coronavirus-vaccine|date=16 December 2020|website=The Tico Times}}</ref>
*Ecuador<ref name="ecuador">{{Cite web|title=Arcsa autoriza ingreso al país de vacuna Pfizer-BioNTech para el Covid-19 – Agencia Nacional de Regulación, Control y Vigilancia Sanitaria|url=https://www.controlsanitario.gob.ec/arcsa-autoriza-ingreso-al-pais-de-vacuna-pfizer-biontech-para-el-covid-19/|access-date=17 December 2020|language=es}}</ref>
*Israel<ref>{{Cite web|title=Israeli Health Minister 'pleased' as FDA approves Pfizer COVID-19 vaccine|url=https://www.jpost.com/breaking-news/fda-approves-pfizer-biontech-covid-19-vaccine-for-emergency-use-nyt-651871|access-date=28 December 2020|website=The Jerusalem Post }}</ref>
*Panama<ref name="panama">{{cite web|access-date=16 December 2020|title=Panama approves Pfizer's COVID-19 vaccine – health ministry|url=https://finance.yahoo.com/news/panama-approves-pfizers-covid-19-010942802.html|publisher=Yahoo! Finance}}</ref>
*Chile<ref name="chile">{{cite web|access-date=17 December 2020|title=Chile approves Pfizer-BioNTech Covid-19 vaccine for emergency use|url=https://www.straitstimes.com/world/chile-approves-pfizer-biontech-covid-19-vaccine-for-emergency-use|date=17 December 2020|website=The Straits Times}}</ref>
*Qatar<ref>{{cite web|access-date=24 December 2020|title=Qatar, Oman to receive Pfizer-BioNTech COVID-19 vaccine this week|url=https://www.reuters.com/article/us-health-coronavirus-vaccine-qatar/qatar-oman-to-receive-pfizer-biontech-covid-19-vaccine-this-week-idUSKBN28U0VE|publisher=Reuters}}</ref>
*UAE<ref>{{Cite web|date=23 December 2020|title=Dubai approves the Pfizer-BioNTech vaccine which will be free of charge|url=https://emirateswoman.com/dubai-approves-the-pfizer-biontech-vaccine-for-free/|access-date=28 December 2020|website=Emirates Woman}}</ref>
*Argentina<ref>{{cite web|url=https://www.lanacion.com.ar/sociedad/coronavirus-argentina-anmat-aprobo-uso-emergencia-vacuna-nid2548852|title=Coronavirus en la Argentina: La ANMAT aprobo el uso de emergencia de la vacuna Pfizer|access-date=23 December 2020|website=La Nación|language=es}}</ref>
*Iraq<ref>{{Cite web|title=Iraq grants emergency approval for Pfizer COVID-19 vaccine|url=https://www.msn.com/en-ae/news/other/iraq-grants-emergency-approval-for-pfizer-covid-19-vaccine/ar-BB1cgvD6|access-date=27 December 2020|publisher=MSN}}</ref>
*WHO<ref>{{Cite web|date=2021-01-01|title=WHO clears Pfizer-BioNTech coronavirus vaccine for emergency use|url=https://newsd.in/who-clears-pfizer-biontech-coronavirus-vaccine-for-emergency-use/|access-date=2021-01-01|website=Newsd.in|language=en}}</ref>
}}
|'''Authorized'''
{{smalldiv|1=
*Saudi Arabia<ref>{{Cite web|date=10 December 2020|title=Coronavirus: Saudi Arabia approves Pfizer COVID-19 vaccine for use|url=https://english.alarabiya.net/en/coronavirus/2020/12/10/Coronavirus-Saudi-Arabia-approves-Pfizer-COVID-19-vaccine-for-use|access-date=10 December 2020|website=Al Arabiya English}}</ref><ref>{{Cite news|last1=Zimmer|first1=Carl|last2=Corum|first2=Jonathan|last3=Wee|first3=Sui-Lee|date=10 June 2020|title=Coronavirus Vaccine Tracker|work=[[The New York Times]]|url=https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html|access-date=12 December 2020|issn=0362-4331}}</ref>
*Switzerland<ref name="Swiss authorization">{{cite press release |title=Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland |url=https://www.bag.admin.ch/bag/en/home/das-bag/aktuell/medienmitteilungen.msg-id-81761.html |publisher=Swiss Agency for Therapeutic Products (Swissmedic) |date=19 December 2020 |access-date=19 December 2020}}</ref>
*EU<ref name="EU PR 20201221" /><ref name="eu vac">{{cite web |url=https://ec.europa.eu/commission/presscorner/detail/en/qanda_20_2467 |title=Questions and Answers: COVID-19 vaccination in the EU |date=21 December 2020 |website=[[European Commission]] |access-date=21 December 2020 }}</ref>
*Norway<ref name="">Norwegian authorization">{{cite press release |title=Koronavaksinen fra BioNTech og Pfizer (Comirnaty) får betinget godkjenning i Europa. |url=https://legemiddelverket.no/nyheter/status-pa-koronavaksiner-under-godkjenning-per-211220 |publisher=Statens legemiddelverk |date=21 December 2020 |access-date=25 December 2020}}</ref>
*Iceland<ref name="">Icelandic authorization">{{cite press release |title=COVID-19: Bóluefninu Comirnaty frá BioNTech/Pfizer hefur verið veitt skilyrt íslenskt markaðsleyfi. |url=https://www.lyfjastofnun.is/frettir/covid-19-boluefninu-comirnaty-fra-biontech-pfizer-hefur-verid-veitt-skilyrt-islenskt-markadsleyfi/ |publisher=Lyfjastofnun |date=21 December 2020 |access-date=26 December 2020}}</ref>
*Faroe Islands<ref name="Danish authorization">{{cite press release |title=Første vaccine mod COVID19 godkendt i EU |url=https://laegemiddelstyrelsen.dk/da/nyheder/2020/foerste-vaccine-mod-covid19-godkendt-i-eu/ |publisher=Lægemiddelstyrelsen |date=21 December 2020 |access-date=26 December 2020}}</ref>
*Greenland<ref name="Danish authorization" />
*Serbia<ref>{{cite news |url=https://balkaninsight.com/2020/12/21/serbia-leads-region-in-expecting-covid-19-vaccines-within-days/|work=BalkanInsight |date=21 December 2020 |title=Serbia leads region in expecting COVID-19 vaccines within days|accessdate=26 December 2020}}</ref><ref>{{cite news |url=https://www.srbija.gov.rs/vest/en/165409/first-shipment-of-pfizer-biontech-vaccine-arrives-in-serbia.php|work=Serbian government website|date=22 December 2020 |title= First shipment of Pfizer-BioNTech vaccine arrives in Serbia|accessdate=26 December 2020}}</ref>
</small>
}}
|}

===လၟောဝ်ဝက်သိန်ဂမၠိုင် Vaccine candidates===
{| class="wikitable sortable"
|+လၟောဝ်ဝက်သိန် ကဝ်ဝိဒ်=၁၉ မနွံပ္ဍဲကာလစွမ် ပထမ-တတိယ<br>COVID‑19 candidate vaccines in Phase I{{ndash}}III trials<ref name=london/><ref name="milken">{{cite web|date=8 December 2020|title=COVID-19 vaccine tracker (Choose vaccines tab, apply filters to view select data)|url=https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viwDBH7b6FjmIBX5x?blocks=hide|access-date=11 December 2020|publisher=Milken Institute|lay-url=https://milkeninstitute.org/covid-19-tracker}}</ref><ref name=who-tracker/>
|-
!လၟောဝ်ဝက်သေန်ဂမၠိုင်<br>ညးမကၠောန်ဗဒှ် ကေုာံ ညးမဒုင်ပစ္စဲ<br>Vaccine candidates,<br />developers, and sponsors
!ကွတ်<br>Technology
!ကာလစွမ် လၟုဟ် <br>Current phase (participants)<br />design
!ကာလစွမ်မတုဲဒှ် <br>Completed phase{{efn-la|Latest Phase with published results.}} (participants)<br />Immune response
!မကဵုအခေါင်စကာ နဒဒှ် ကာတၟေင် <br>Emergency use authorization
|- valign="top"
|'''Ad26.COV2.S'''<ref>{{Cite web|title=A Study of Ad26.COV2.S in Adults|url=https://clinicaltrials.gov/ct2/show/NCT04436276|access-date=23 August 2020|website=[[ClinicalTrials.gov]]|date=4 August 2020|archive-date=16 September 2020|archive-url=https://web.archive.org/web/20200916063346/https://clinicaltrials.gov/ct2/show/NCT04436276|url-status=live}}</ref><ref>{{Cite web|title=A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants|url=https://clinicaltrials.gov/ct2/show/NCT04505722|url-status=live|archive-url=https://web.archive.org/web/20200926145744/https://clinicaltrials.gov/ct2/show/NCT04505722|archive-date=26 September 2020|website=ClinicalTrials.gov|publisher=US National Library of Medicine}}</ref>
[[Janssen Pharmaceutica]] (Johnson & Johnson), [[Beth Israel Deaconess Medical Center|BIDMC]]
|Non-[[Viral replication|replicating]] [[viral vector]] (adenovirus serotype 26)
| {{ClinicalStudyInfo|align=left|phase=3|participants=40000|description=Randomized, double-blinded, placebo-controlled
Temporarily paused on 13 October 2020, due to an unexplained illness in a participant.<ref>{{cite news | title=Johnson & Johnson pauses its coronavirus vaccine trial because of a volunteer's 'unexplained illness.' | website=[[The New York Times]] | date=13 October 2020 | url=https://www.nytimes.com/2020/10/12/world/johnson-johnson-pauses-its-coronavirus-vaccine-trial-because-of-a-volunteers-unexplained-illness.html | access-date=25 October 2020 | authors=Virginia Hughes, Katie Thomas, Carl Zimmer, Katherine J. Wu | archive-date=24 October 2020 | archive-url=https://web.archive.org/web/20201024023926/https://www.nytimes.com/2020/10/12/world/johnson-johnson-pauses-its-coronavirus-vaccine-trial-because-of-a-volunteers-unexplained-illness.html | url-status=live }}</ref> Johnson & Johnson announced, on 23 October, that they are preparing to resume the trial in the US.<ref>{{cite news | url=https://www.wsj.com/articles/covid-19-vaccine-trial-from-astrazeneca-oxford-can-resume-in-u-s-11603476923 | title=Pivotal Studies of Covid-19 Vaccines From AstraZeneca, J&J Resuming | work=[[The Wall Street Journal]] | first1=Thomas M. | last1=Burton | first2=Peter | last2=Loftus | date=23 October 2020 | name-list-style=vanc | access-date=26 October 2020 | archive-date=26 October 2020 | archive-url=https://web.archive.org/web/20201026061035/https://www.wsj.com/articles/covid-19-vaccine-trial-from-astrazeneca-oxford-can-resume-in-u-s-11603476923 | url-status=live }}</ref><ref>{{cite news | url=https://www.washingtonpost.com/health/2020/10/23/jj-vaccine-trial-to-resume/ | title=Johnson & Johnson, AstraZeneca coronavirus vaccine trials set to resume | work=[[The Washington Post]] | date=24 October 2020 | first=Carolyn Y. | last=Johnson | name-list-style=vanc | access-date=26 October 2020 | archive-date=26 October 2020 | archive-url=https://web.archive.org/web/20201026113132/https://www.washingtonpost.com/health/2020/10/23/jj-vaccine-trial-to-resume/ | url-status=live }}</ref>
|locations=United States, Argentina, Brazil, Chile, Colombia, Mexico, Peru, the Philippines, South Africa and Ukraine
|duration= Jul 2020{{snd}}2023
}}
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=1045}}
|'''Pending'''<br />
*<small>Canada<ref name=hcapps/></small>
*<small>EU: EMA<ref name="EU Ad26.COV2.S rolling review" /></small>
*<small>South Africa<ref>[https://www.msn.com/en-za/news/other/johnson-and-johnson-the-first-to-apply-for-covid-vaccine-registration-as-south-africa-starts-review-process/ar-BB1bZnjI "Johnson & Johnson the first to apply for Covid-19 vaccine registration as South Africa starts review process"] MSN. 17 December 2020.</ref></small>
|- valign="top"
|'''NVX-CoV2373'''<wbr/><ref name="NCT04368988">{{cite web |title=Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant |url=https://clinicaltrials.gov/ct2/show/NCT04368988 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04368988 |date=30 April 2020 |access-date=14 July 2020 |archive-date=14 July 2020 |archive-url=https://web.archive.org/web/20200714224741/https://clinicaltrials.gov/ct2/show/NCT04368988 |url-status=live }}</ref><br />[[Novavax]]
|[[Severe acute respiratory syndrome coronavirus 2|SARS-CoV-2]] [[Recombinant vaccine|recombinant]] [[Peplomer|spike protein]] [[nanoparticle]] with [[Immunologic adjuvant|adjuvant]]
|{{ClinicalStudyInfo|align=left|phase=3|participants=45000|description=Randomised, observer-blinded, placebo-controlled trial<ref name="NCT04583995">{{cite web | url = https://clinicaltrials.gov/ct2/show/NCT04583995 | title = A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom | access-date = 22 November 2020 | website=ClinicalTrials.gov }}</ref>|locations=UK, India (15000);<ref>{{cite news |last1=Yengkhom |first1=Sumati |title=Three Kolkata institutes queue up for corona vaccine trials {{!}} Kolkata News |url=https://timesofindia.indiatimes.com/city/kolkata/3-kol-institutes-queue-up-for-corona-vaccine-trials/articleshow/79359532.cms |work=The Times of India |date=23 November 2020 }}</ref> US, Mexico (30000)<ref>{{Cite web|title=A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2 - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT04611802|access-date=2020-12-30|website=clinicaltrials.gov|language=en}}</ref>|duration=Sep 2020{{snd}}Jan 2021 (UK, India); Dec 2020{{snd}}Mar 2021 (US, Mexico)}}
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=131}} [[Immunoglobulin G|IgG]] and [[neutralizing antibody]] response with adjuvant after [[booster dose]]<ref name="pmid32877576">{{cite journal | vauthors = Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter JD, Griffin P, Wilkinson B, Glenn GM | display-authors=6 | title = Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine | journal = The New England Journal of Medicine | date = September 2020 | volume=383 | issue=24 | pages=2320–2332 | pmid = 32877576 | pmc = 7494251 | doi = 10.1056/NEJMoa2026920 }}</ref>
| '''Pending'''<br />
*<small>Mexico: [[COFEPRIS]]<ref>{{Cite news|last=Ebrard|first=Marcelo|title=Informe de avance sobre vacunas al 15 de diciembre de 2020.|url=https://twitter.com/m_ebrard/status/1338882415197085696|access-date=17 December 2020}}{{Primary source inline|date=December 2020}}</ref></small>
|- valign="top"
|'''[[BBV152]]''' 
[[Bharat Biotech]], [[Indian Council of Medical Research]]

[[Trade name]]:<small>'''Covaxin'''</small>
|[[Severe acute respiratory syndrome coronavirus 2|Inactivated SARS-CoV-2]]
|{{ClinicalStudyInfo|align=left|phase=3|participants=25800|description=Randomised, observer-blinded, placebo-controlled<ref>{{Cite web|title=An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers |type=Registry |id=NCT04641481| url=https://clinicaltrials.gov/ct2/show/NCT04641481|access-date=26 November 2020|website=ClinicalTrials.gov}}</ref>
|locations=India
|duration=Nov 2020 {{En dash}} Mar 2022
}}
|{{ClinicalStudyInfo|align=left|phase=1|participants=375}} Dose-dependent [[neutralizing antibody]] response on two-dose schedule.<br />
Pending Phase II reports<ref>{{cite web |title=Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers |url=https://clinicaltrials.gov/ct2/show/NCT04471519 |type=Registry |id=NCT04471519|website=ClinicalTrials.gov }}</ref>
| '''Pending'''<br />

*<small>India: [[Drugs Controller General of India|DCGI]]<ref>{{cite news |last1=Dwivedi |first1=Sukirti |last2=Dey |first2=Stela |title=Bharat Biotech Seeks Emergency Use Approval For Covaxin |url=https://www.ndtv.com/india-news/bharat-biotech-seeks-emergency-use-authorisation-for-coronavirus-vaccine-covaxin-report-2335492 |work=NDTV.com |date=8 December 2020}}</ref></small>
|- valign="top"
|'''CoVLP'''<ref>{{Cite web|date=13 November 2020|title=GSK, Medicago launch phase 2/3 clinical trials of plant-derived COVID-19 vaccine|url=http://www.pmlive.com/pharma_news/gsk,_medicago_launch_phase_23_clinical_trials_of_plant-derived_covid-19_vaccine_1356854|access-date=16 November 2020|website=PMLive}}</ref>
[[Medicago Inc.|Medicago]], [[GlaxoSmithKline|GSK]]
|[[Recombinant vaccine|Recombinant]], [[Plant expressed vaccine|plant-based]] [[virus-like particle]]s{{efn-la|name="Medicago-technology"|Virus-like particles grown in ''[[Nicotiana benthamiana]]''<ref name="np-medicago">{{cite news | first=Vishwadha | last=Chander | work=National Post | agency=Reuters | title=Canada's Medicago begins human trials of plant-based COVID-19 vaccine | date=14 July 2020 | url=https://nationalpost.com/news/canada/canadas-medicago-begins-human-trials-of-plant-based-covid-19-vaccine | access-date=14 July 2020 | name-list-style=vanc | archive-date=1 November 2020 | archive-url=https://web.archive.org/web/20201101220834/https://nationalpost.com/news/canada/canadas-medicago-begins-human-trials-of-plant-based-covid-19-vaccine | url-status=live }}</ref>}} with [[GlaxoSmithKline|GSK]] [[Immunologic adjuvant|adjuvant]]
|{{ClinicalStudyInfo|align=left|phase=2|endphase=3|participants=30,612
|description=Event-driven, randomized, observer blinded, placebo-controlled<ref>{{Cite journal|last=Medicago|date=18 November 2020|title=Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older|url=https://clinicaltrials.gov/ct2/show/NCT04636697}}</ref>
|locations=Canada
|duration=Nov 2020 {{En dash}} Apr 2022
}}
|{{ClinicalStudyInfo|align=left|phase=1|participants=180
|description=Neutralizing antibodies at day 42 after the first injection (day 21 after the second injection) were at levels 10x that of COVID-19 survivors.
}}
|
|- valign="top"
|'''[[ZF2001]]''' <ref name=london/><br />Anhui Zhifei Longcom Biopharmaceutical Co. Ltd.
[[Trade name]]: '''<small>RBD-Dimer</small>'''
|[[Recombinant vaccine|Recombinant]] [[subunit vaccine]]
|{{ClinicalStudyInfo|align=left|phase=3|participants=29,000|description=randomized, double-blind, placebo-controlled<ref>{{cite journal |title=A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19 - Full Text View - ClinicalTrials.gov |journal=Clinicaltrials.gov |url=https://clinicaltrials.gov/ct2/show/NCT04646590#wrapper }}</ref>|locations=China, Ecuador, Indonesia, Malaysia, Pakistan, Uzbekistan<ref>{{cite web |last1=Pinghui |first1=Zhuang |title=Fifth Chinese Covid-19 vaccine candidate ready to enter phase 3 trials |url=https://www.scmp.com/news/china/science/article/3110690/coronavirus-chinas-cnbg-set-review-covid-19-vaccine-phase-3 |work=South China Morning Post |access-date=26 December 2020 |date=20 November 2020}}</ref><ref>{{cite web |last1=Ying |first1=Teoh Pei |title=MYEG to conduct phase 3 clinical trial for China's Covid-19 vaccine in Msia {{!}} New Straits Times |url=https://www.nst.com.my/news/nation/2020/12/647456/myeg-conduct-phase-3-clinical-trial-chinas-covid-19-vaccine-msia |work=New Straits Times |access-date=28 December 2020 |date=7 December 2020}}</ref>|duration=Dec 2020{{snd}}Apr 2022}}
|{{ClinicalStudyInfo|align=left|phase=2|participants=900|description=Interventional; randomized, double-blind, placebo-controlled<ref name="NCT04466085">{{cite web |title=A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years |url=https://clinicaltrials.gov/ct2/show/NCT04466085 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04466085 |date=10 July 2020 |access-date=26 August 2020 |archive-date=28 July 2020 |archive-url=https://web.archive.org/web/20200728095036/https://clinicaltrials.gov/ct2/show/NCT04466085 |url-status=live }}</ref>
|locations=[[Chongqing]]
|duration=Jun 2020{{snd}}Sep 2021}}
|
|- valign="top"
|'''Zorecimeran (CVnCoV)'''<wbr/><br />[[CureVac]], [[Coalition for Epidemic Preparedness Innovations|CEPI]]
|[[modRNA]]
|{{ClinicalStudyInfo|align=left|phase=3|participants=36500|references=<ref name="2020-003998-22">{{cite web |title=COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
|url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003998-22/DE |date=19 November 2020 |access-date=19 December 2020 |website=EU Clinical Trials Register |id=2020-003998-22}}</ref>
|description=Phase 2b/3: Multicenter efficacy and safety trial in adults
|locations=Argentina, Belgium, Colombia, Dominican Republic, France, Germany, Mexico, Netherlands, Panama, Peru, Spain
|duration=Nov 2020{{snd}}?
}}
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=944|references=<ref name="NCT04449276">{{cite web |title=A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults |url=https://clinicaltrials.gov/ct2/show/NCT04449276 |website=[[ClinicalTrials.gov]] |id=NCT04449276 |date=26 June 2020 |access-date=14 July 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084840/https://clinicaltrials.gov/ct2/show/NCT04449276/ |url-status=live }}</ref><ref name="NCT04515147">{{cite web |title=A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults |url=https://clinicaltrials.gov/ct2/show/NCT04515147 |website=[[ClinicalTrials.gov]] |id=NCT04515147 |date=17 August 2020 |access-date=28 August 2020 |archive-date=23 August 2020 |archive-url=https://web.archive.org/web/20200823000237/https://clinicaltrials.gov/ct2/show/NCT04515147 |url-status=live }}</ref>
|description=Phase 1 (284): Partially blind, controlled, dose-escalation to evaluate safety, reactogenicity and immunogenicity.
Phase 2a (660):Partially observer-blind, multicenter, controlled, dose-confirmation.
|locations=Belgium (P1), Germany (P1), Panama (2a), Peru (2a)
|duration=Jun 2020{{snd}}Oct 2021
}}
|
|-  valign="top"
|'''IIBR-100'''<wbr/><ref name="NCT04608305">{{cite web |title=A Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults |url=https://clinicaltrials.gov/ct2/show/NCT04608305 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04608305 |date=1 November 2020}}</ref><br />[[Ministry of Health (Israel)|The Israel Institute for Biological research]]
[[Trade name]]: '''<small>Brilife</small>'''
|[[Recombinant vaccine|Recombinant]] [[vesicular stomatitis virus]]
|{{ClinicalStudyInfo|align=left|phase=2|participants=1000 |references=<ref>{{cite web |title=As Israel goes vaccine-wild, will the homegrown version lose its shot?|url=https://www.timesofisrael.com/as-israel-goes-vaccine-wild-will-the-homegrown-version-lose-its-shot/|website=Times of Israel |date=29 December 2020|access-date=1 January  2021|url-status=live}}</ref>
|description=
|locations=Israel
|duration= Dec 2020{{snd}}spring 2021
}}
|{{ClinicalStudyInfo|align=left|phase=1|participants=80|references=<ref name="NCT04608305"/>
|description=Subjects (18-55 years old) randomly receiving a single administration of IIBR-100 at the low, mid, or high dose of saline or two administrations at a low dose, or saline, 28 days apart.
|locations=Israel
|duration= Oct{{snd}}Nov 2020
}}
|
|-  valign="top"
|'''INO-4800'''<wbr/>{{efn-la|name="INO-4800-phase"|South Korean Phase I–II in parallel with Phase I in the US}}<ref name="NCT04336410">{{cite web |title=Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers |url=https://clinicaltrials.gov/ct2/show/NCT04336410 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04336410 |date=7 April 2020 |access-date=14 July 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084843/https://clinicaltrials.gov/ct2/show/NCT04336410/ |url-status=live }}</ref><ref>{{Cite web|url=https://www.ivi.int/ivi-inovio-and-knih-to-partner-with-cepi-in-a-phase-i-ii-clinical-trial-of-inovios-covid-19-dna-vaccine-in-south-korea/|title=IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID-19 DNA vaccine in South Korea|publisher=International Vaccine Institute|date=16 April 2020|access-date=23 April 2020}}</ref><br />[[Inovio Pharmaceuticals|Inovio]], [[Coalition for Epidemic Preparedness Innovations|CEPI]], [[Korea Centers for Disease Control and Prevention|Korea National Institute of Health]], [[International Vaccine Institute]]
|[[DNA vaccination#Plasmid vectors|DNA plasmid]] delivered by [[electroporation]]
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=40
|locations=United States, South Korea
|duration=Apr{{ndash}}Nov 2020
}}
|{{ClinicalStudyInfo|align=left|sortvalue=0a|Pending Phase I report}}
|
|- valign="top"
|'''EpiVacCorona'''<wbr/><ref name="NCT04527575">{{cite web |title=Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19 (EpiVacCorona) |url=https://clinicaltrials.gov/ct2/show/NCT04527575 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04368988 |date=22 September 2020 |access-date=16 November 2020}}</ref><br />[[State Research Center of Virology and Biotechnology VECTOR|Vector]]
|[[Peptide vaccine|Vaccine based on peptide antigens]]<ref name="NCT04527575" />
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=100|description=Simple, blind, placebo-controlled, randomized study of safety, reactogenicity and immunogenicity<ref name="NCT04527575" />
|locations=Russia
|duration=Jul 2020<ref name="NCT04527575" />{{snd}}?}}
|{{ClinicalStudyInfo|align=left|sortvalue=0a|Pending Phase I–II report}}
|
|- valign="top"
|''Unnamed''<wbr/><ref name="NCT04412538">{{cite web |title=Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04412538 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04412538 |date=2 June 2020 |access-date=14 July 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084852/https://clinicaltrials.gov/ct2/show/NCT04412538/ |url-status=live }}</ref><br />[[Peking Union Medical College|Chinese Academy of Medical Sciences]]
|[[Inactivated vaccine|Inactivated]] [[Severe acute respiratory syndrome coronavirus 2|SARS-CoV-2]]
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=942|description=Randomized, double-blinded, single-center, placebo-controlled
|locations=[[Chengdu]]
|duration=Jun 2020{{snd}}Sep 2021
}}
|{{ClinicalStudyInfo|align=left|}}
|
|- valign="top"
|'''AG0301-COVID‑19'''<wbr/><ref name="NCT04463472">{{cite web |title=Study of COVID-19 DNA Vaccine (AG0301-COVID19) |url=https://clinicaltrials.gov/ct2/show/NCT04463472 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04463472 |date=9 July 2020 |access-date=14 July 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084854/https://clinicaltrials.gov/ct2/show/NCT04463472/ |url-status=live }}</ref><br />AnGes Inc.,<ref name="anges-inc">{{cite web |url=https://www.anges.co.jp/en/company/index.html |title=About AnGes – Introduction |website=AnGes, Inc. |access-date=1 August 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084856/https://www.anges.co.jp/en/company/index.html/ |url-status=live }}</ref> [[Japan Agency for Medical Research and Development|AMED]]
|[[DNA vaccination#Plasmid vectors|DNA plasmid]]
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=30|description=Non-randomized, single-center, two doses
|locations=[[Osaka]]
|duration=Jun 2020{{snd}}Jul 2021
}}
|{{ClinicalStudyInfo|align=left|}}
|
|- valign="top"
|'''Lunar-COV19/ARCT-021'''<ref>{{Cite web|title=CTI and Arcturus Therapeutics Announce Initiation of Dosing of COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study|url=https://www.bioindustry.org/news-listing/cti-and-arcturus-therapeutics-announce-initiation-of-dosing-of-covid-19-starr-mrna-vaccine-candidate-lunar-cov19-arct-021-in-a-phase-12-study.html|access-date=23 August 2020|date=13 August 2020|publisher=UK BioIndustry Association|archive-date=11 October 2020|archive-url=https://web.archive.org/web/20201011084858/https://www.bioindustry.org/news-listing/cti-and-arcturus-therapeutics-announce-initiation-of-dosing-of-covid-19-starr-mrna-vaccine-candidate-lunar-cov19-arct-021-in-a-phase-12-study.html/|url-status=live}}</ref><ref>{{Cite web|title=Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects|url=https://clinicaltrials.gov/ct2/show/NCT04480957|access-date=23 August 2020|website=clinicaltrials.gov|archive-date=11 October 2020|archive-url=https://web.archive.org/web/20201011084910/https://clinicaltrials.gov/ct2/show/NCT04480957/|url-status=live}}</ref>
[[Arcturus Therapeutics]]
|[[Messenger RNA|mRNA]]
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=92|description=Randomized, double-blinded
|locations=Singapore
|duration=Aug 2020{{snd}}?
}}
|{{ClinicalStudyInfo|align=left|}}
|
|- valign="top"
|'''COVID‑19/aAPC'''<wbr/><ref name="NCT04299724">{{cite web |title=Safety and Immunity of Covid-19 aAPC Vaccine |website=[[ClinicalTrials.gov]] |url=https://clinicaltrials.gov/ct2/show/NCT04299724 |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04299724 |date=9 March 2020 |access-date=14 July 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084913/https://clinicaltrials.gov/ct2/show/NCT04299724/ |url-status=live }}</ref><br />Shenzhen Genoimmune Medical Institute<ref name="shenzhen-genoimmune-medical-institute">{{cite web |url=http://www.szgimi.org/en/about.php |title=About Us |publisher=Shenzhen Genoimmune Medical Institute |access-date=1 August 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084919/http://www.szgimi.org/en/about.php/ |url-status=live }}</ref>
|[[Lentiviral vector in gene therapy|Lentiviral vector]] with [[minigene]] modifying [[Artificial antigen presenting cells|aAPCs]]
|{{ClinicalStudyInfo|align=left|phase=1|participants=100
|locations=[[Shenzhen]]
|duration=Mar 2020{{snd}}2023
}}
|{{ClinicalStudyInfo|align=left|}}
|
|- valign="top"
|'''LV-SMENP-DC'''<wbr/><ref name="NCT04276896">{{cite web |url=https://clinicaltrials.gov/ct2/show/NCT04276896 |title=Immunity and Safety of Covid-19 Synthetic Minigene Vaccine |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04276896 |date=19 February 2020 |access-date=14 July 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084923/https://clinicaltrials.gov/ct2/show/NCT04276896/ |url-status=live }}</ref><br />Shenzhen Genoimmune Medical Institute<ref name="shenzhen-genoimmune-medical-institute"/>
|[[Lentiviral vector in gene therapy|Lentiviral vector]] with [[minigene]] modifying [[dendritic cells|DCs]]
|{{ClinicalStudyInfo|align=left|phase=1|participants=100
|locations=[[Shenzhen]]
|duration=Mar 2020{{snd}}2023
}}
|{{ClinicalStudyInfo|align=left|}}
|
|- valign="top"
|'''LNP-nCoVsaRNA'''<wbr/><ref name="ISRCTN17072692">{{cite journal |title=Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women |website=ISRCTN |type=Registry |id=ISRCTN17072692 |doi=10.1186/ISRCTN17072692 |date=22 May 2020 |last1=Ward |first1=Denise |last2=McCormack |first2=Sheena |doi-access=free |name-list-style=vanc }}</ref><br />[[Medical Research Council (United Kingdom)|MRC]] [[clinical trials unit]] at [[Imperial College London]]
|[[RNA vaccine|mRNA]]
|{{ClinicalStudyInfo|align=left|phase=1|participants=105|description=Randomized trial, with dose escalation study (15) and expanded safety study (at least 200)
|locations=United Kingdom
|duration=Jun 2020{{snd}}Jul 2021
}}
|{{ClinicalStudyInfo|align=left|}}
|
|- valign="top"
|'''ZyCoV-D'''<wbr/><ref>{{Cite web|website=ctri.nic.in|publisher=[[Clinical Trials Registry – India|Clinical Trials Registry India]]|title=A prospective, randomized, adaptive, phase I/II clinical study to evaluate the safety and immunogenicity of Novel Corona Virus −2019-nCov vaccine candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects|type=Registry |id=CTRI/2020/07/026352 |url=http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45306|url-status=live|archive-url=https://web.archive.org/web/20201122022620/http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45306|archive-date=22 November 2020|date=15 December 2020}}</ref><br />
[[Cadila Healthcare]]
|[[DNA plasmids|DNA plasmid]] expressing [[SARS-CoV-2]] [[S protein]]
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=1000 |description=Interventional; randomized, double-blind, placebo-controlled<ref>{{Cite journal|last1=Rawat|first1=Kajal|last2=Kumari|first2=Puja|last3=Saha|first3=Lekha|date=24 November 2020|title=COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies|url=https://pubmed.ncbi.nlm.nih.gov/33245898|journal=European Journal of Pharmacology|volume=892|pages=173751|doi=10.1016/j.ejphar.2020.173751|issn=1879-0712|pmc=7685956|pmid=33245898}}</ref><ref>{{Cite news|last=Thacker|first=Teena|title=Zydus Cadila to test ZyCoV-D on 30,000 patients in Phase-3 trials|work=The Economic Times|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-cadila-to-test-zycov-d-on-30000-patients-in-phase-3-trials/articleshow/79088859.cms?from=mdr|access-date=16 December 2020}}</ref>
|locations=India
|duration=Jul 2020{{snd}}Apr 2021
}}
|{{ClinicalStudyInfo|align=left|}}
|
|- valign="top"
|'''GX-19'''<wbr/><ref name="NCT04445389">{{cite web |title=Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults |url=https://clinicaltrials.gov/ct2/show/NCT04445389 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04445389 |date=24 June 2020 |access-date=14 July 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084931/https://clinicaltrials.gov/ct2/show/NCT04445389/ |url-status=live }}</ref><ref name="gen-reut">{{cite news |title=S. Korea's Genexine begins human trial of coronavirus vaccine |url=https://www.reuters.com/article/health-coronavirus-genexine-vaccine-idUSL4N2DW1T3 |access-date=25 June 2020 |publisher=Reuters |date=19 June 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084934/https://www.reuters.com/article/health-coronavirus-genexine-vaccine-idUSL4N2DW1T3/ |url-status=live }}</ref><br />Genexine consortium,<ref>{{cite news |title=Genexine consortium's Covid-19 vaccine acquires approval for clinical trails in Korea |url=https://www.ivi.int/genexine-consortiums-covid-19-vaccine-acquires-approval-for-clinical-trails-in-korea/ |date=11 June 2020 |access-date=1 August 2020}}</ref> [[International Vaccine Institute]]
|[[DNA vaccination|DNA]]
|{{ClinicalStudyInfo|align=left|phase=1|participants=40
|locations=[[Seoul]]
|duration=Jun 2020{{snd}}Jun 2022
}}
|{{ClinicalStudyInfo|align=left|}}
|
|- valign="top"
|'''SCB-2019'''<wbr/><ref name="NCT04405908">{{cite web |title=SCB-2019 as COVID-19 Vaccine |url=https://clinicaltrials.gov/ct2/show/NCT04405908 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04405908 |date=28 May 2020 |access-date=14 July 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084942/https://clinicaltrials.gov/ct2/show/NCT04405908/ |url-status=live }}</ref><ref name="clover-cta">{{cite web |title=Clover Biopharmaceuticals starts Phase I Covid-19 vaccine trial |url=https://www.clinicaltrialsarena.com/news/clover-vaccine-covid-19-trial/ |publisher=Clinical Trials Arena |access-date=25 June 2020 |date=20 June 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084945/https://www.clinicaltrialsarena.com/news/clover-vaccine-covid-19-trial// |url-status=live }}</ref><br />Clover Biopharmaceuticals,<ref name="clover-biopharma">{{cite web |url=http://www.cloverbiopharma.com/index.php?m=content&c=index&a=lists&catid=12 |title=About Us |website=Clover Biopharmaceuticals |access-date=1 August 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084948/http://www.cloverbiopharma.com/index.php?m=content&c=index&a=lists&catid=12%2F |url-status=live }}</ref> [[GlaxoSmithKline|GSK]]
|[[Peplomer|Spike protein]] [[Protein trimer|trimeric]] [[Protein subunit#Subunit Vaccines|subunit]] with [[GlaxoSmithKline|GSK]] [[Immunologic adjuvant|adjuvant]]
|{{ClinicalStudyInfo|align=left|phase=1|participants=150
|locations=[[Perth]]
|duration=Jun 2020{{snd}}Mar 2021
}}
|{{ClinicalStudyInfo|align=left|}}
|
|- valign="top"
|'''COVAX-19'''<wbr/><ref name="NCT04453852">{{cite web |title=Monovalent Recombinant COVID19 Vaccine (COVAX19) |url=https://clinicaltrials.gov/ct2/show/NCT04453852 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04453852 |date=1 July 2020 |access-date=14 July 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011085001/https://clinicaltrials.gov/ct2/show/NCT04453852/ |url-status=live }}</ref><br />Vaxine Pty Ltd<ref name="vaxine-pty">{{cite web |url=http://vaxine.net/ |title=Vaxine |access-date=1 August 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011085004/https://vaxine.net// |url-status=live }}</ref>
|[[Recombinant vaccine|Recombinant]] [[protein]]
|{{ClinicalStudyInfo|align=left|phase=1|participants=40
|locations=[[Adelaide]]
|duration=Jun 2020{{snd}}Jul 2021
}}
|{{ClinicalStudyInfo|align=left|}}
|
|- valign="top"
|''Unnamed''<wbr/><ref name="ChiCTR2000034112">{{cite web |url=http://www.chictr.org.cn/showprojen.aspx?proj=55524 |title=A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18–59 years and 60 years and above |website=Chinese Clinical Trial Register |type=Registry |id=ChiCTR2000034112 |date=24 June 2020 |access-date=6 July 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011085018/http://www.chictr.org.cn/showprojen.aspx?proj=55524%2F |url-status=live }}</ref><br />[[PLA Academy of Military Science]], Walvax Biotech<ref name="walvax">{{cite web |url=http://www.walvax.com/wosen/28.aspx |title=Company introduction |website=Walvax Biotechnology |access-date=1 August 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011085028/http://www.walvax.com/wosen/28.aspx/ |url-status=live }}</ref>
|[[RNA vaccine|mRNA]]
|{{ClinicalStudyInfo|align=left|phase=1|participants=168
|locations=China
|duration=Jun 2020{{snd}}Dec 2021
}}
|{{ClinicalStudyInfo|align=left|}}
|
|- valign="top"
|'''SARS-CoV-2 Sclamp'''/'''[[V451]]'''<wbr/><ref name="NCT04495933">{{cite web |url=https://clinicaltrials.gov/ct2/show/NCT04495933 |title=A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04495933 |date=3 August 2020 |access-date=4 August 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011085041/https://clinicaltrials.gov/ct2/show/NCT04495933/ |url-status=live }}</ref><ref>{{Cite web|title=UQ-CSL V451 Vaccine|url=https://www.precisionvaccinations.com/vaccines/uq-csl-v451-vaccine|access-date=11 December 2020|website=precisionvaccinations.com}}</ref><br />[[University of Queensland|UQ]], [[Syneos Health]], [[Coalition for Epidemic Preparedness Innovations|CEPI]], [[CSL Limited#Seqirus (bioCSL)|Seqirus]]
|[[Molecular clamp]] stabilized [[Peplomer|spike protein]] with [[MF59]]
|{{ClinicalStudyInfo|align=left|phase=1|participants=120|description=Randomised, double-blind, placebo-controlled, dose-ranging
|locations=[[Brisbane]]
|duration=Jul{{ndash}}Oct 2020
}}
|{{ClinicalStudyInfo|align=left|}}
|{{NA}}<br />[[V451 vaccine|Testing and development terminated in December 2020 due to false positive HIV test found among participants]]
|}

==နိဿဲ==
{{reflist}}

==Footnotes==
{{notelist}}

==ဆက်ဗှ်==
* {{cite book|last=Vogel|first=Patric U. B.|date=2020|title=COVID-19 : Suche nach einem Impfstoff|series=Essentials|url=https://link.springer.com/book/10.1007/978-3-658-31340-1|location=Wiesbaden|publisher=Springer Fachmedien Wiesbaden GmbH|doi=10.1007/978-3-658-31340-1|isbn=978-3-658-31340-1|oclc=1199717422}}
* {{cite journal |vauthors=Funk CD, Laferrière C, Ardakani A |title=A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic |journal=Front Pharmacol |volume=11 |page=937 |date=2020 |pmid=32636754 |pmc=7317023 |doi=10.3389/fphar.2020.00937 |doi-access=free}}
* {{cite web | last1=Johnson | first1=Carolyn Y. | last2=Mufson | first2=Steven | name-list-style = vanc | title=Can old vaccines from science's medicine cabinet ward off coronavirus? | website=[[The Washington Post]] | date=11 June 2020 | url=https://www.washingtonpost.com/health/2020/06/11/can-old-vaccines-sciences-medicine-cabinet-ward-off-coronavirus/ }}
* {{cite document | title=Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry | url=https://www.fda.gov/media/139638/download | format=PDF | publisher=U.S. [[Food and Drug Administration]] (FDA) | date=June 2020 | lay-url=https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19 }}
* {{cite web | first1=Carl | last1=Zimmer | first2=Knvul | last2=Sheikh | first3=Noah | last3=Weiland | name-list-style = vanc | title=A New Entry in the Race for a Coronavirus Vaccine: Hope | website=[[The New York Times]] | date=20 May 2020 | url=https://www.nytimes.com/2020/05/20/health/coronavirus-vaccines.html }}
*{{Cite web|last=Haelle|first=Tara|date=12 December 2020|title=Every Covid-19 Vaccine Question You'll Ever Have, Answered|url=https://elemental.medium.com/every-covid-19-vaccine-question-youll-ever-have-answered-9a0eeb334ded|access-date=12 December 2020|website=Medium}}

==လေန် မ္ၚး==
* Wikiquote has quotations related to: [[:en:q:Special:Search/COVID-19 vaccine|''COVID-19 vaccine'']]
* {{cite web | title=Coronavirus Vaccine Tracker | website=[[The New York Times]] | url=https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html }}
* [https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker COVID-19 vaccine tracker, Regulatory Focus]
* {{cite web | title=STAT's Covid-19 Drugs and Vaccines Tracker | work=[[Stat (website)|Stat]] | url=https://www.statnews.com/feature/coronavirus/drugs-vaccines-tracker/#vaccines }}
* {{cite news | title=Biopharma Leaders Unite to Stand with Science | via=[[Business Wire]] | date=8 September 2020 | url=https://www.businesswire.com/news/home/20200908005282/en/ }}
* {{cite web | url=https://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf | title=Protocol mRNA-1273-P301 | publisher=[[Moderna]] }}
* {{cite web | url=https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-09/C4591001_Clinical_Protocol.pdf | title=Protocol C4591001 PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) | publisher=[[Pfizer]] }}
* {{cite web | url=https://s3.amazonaws.com/ctr-med-7111/D8110C00001/52bec400-80f6-4c1b-8791-0483923d0867/c8070a4e-6a9d-46f9-8c32-cece903592b9/D8110C00001_CSP-v2.pdf | title=Protocol AZD1222 – D8110C00001 | publisher=[[AstraZeneca]] }}
* {{cite web | url=https://www.jnj.com/coronavirus/covid-19-phase-3-study-clinical-protocol | format=PDF | title=Protocol VAC31518COV3001; Phase 3 | publisher=[[Janssen Pharmaceutica|Janssen Vaccines & Prevention]] }}
* {{cite web | last=Levine | first=Hallie | title=The 5 Stages of COVID-19 Vaccine Development: What You Need to Know About How a Clinical Trial Works | publisher=Johnson & Johnson | date=23 September 2020 | url=https://www.jnj.com/innovation/the-5-stages-of-covid-19-vaccine-development-what-you-need-to-know-about-how-a-clinical-trial-works }}
* {{cite web | title=COVID-19 vaccines: development, evaluation, approval and monitoring | publisher=[[European Medicines Agency]] | url=https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines-development-evaluation-approval-monitoring }}
* {{cite web | title=Vaccine Development – 101 | publisher=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/vaccine-development-101 }}

[[Category:ပရေင်ထတ်ယုက်]]
[[Category:BEHM]]
